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The monoaminergic systems are the target of several drugs for the treatment of
mood, motor and cognitive disorders as well as neurological conditions. In most cases,
advances have occurred through serendipity, except for Parkinson’s disease where
the pathophysiology led almost immediately to the introduction of dopamine restoring
agents. Extensive neuropharmacological studies first showed that the primary target
of antipsychotics, antidepressants, and anxiolytic drugs were specific components of
the monoaminergic systems. Later, some dramatic side effects associated with older
medicines were shown to disappear with new chemical compounds targeting the
origin of the therapeutic benefit more specifically. The increased knowledge regarding
the function and interaction of the monoaminergic systems in the brain resulting from
in vivo neurochemical and neurophysiological studies indicated new monoaminergic
targets that could achieve the efficacy of the older medicines with fewer side-effects.
Yet, this accumulated knowledge regarding monoamines did not produce valuable
strategies for diseases where no monoaminergic drug has been shown to be effective.
Here, we emphasize the new therapeutic and monoaminergic-based strategies for the
treatment of psychiatric diseases. We will consider three main groups of diseases,
based on the evidence of monoamines involvement (schizophrenia, depression, obesity),
the identification of monoamines in the diseases processes (Parkinson’s disease,
addiction) and the prospect of the involvement of monoaminergic mechanisms (epilepsy,
Alzheimer’s disease, stroke). In most cases, the clinically available monoaminergic drugs
induce widespread modifications of amine tone or excitability through neurobiological
networks and exemplify the overlap between therapeutic approaches to psychiatric and
neurological conditions. More recent developments that have resulted in improved drug
specificity and responses will be discussed in this review.
Keywords: antipsychotic, antidepressant, monoamine oxidase inhibitor, multi-target pharmacology,
neurodegenerative diseases, stroke, antiparkinsonian treatments, drug addiction
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INTRODUCTION
Monoaminergic systems are important cellular targets in a variety
of neuropsychiatric and neurological conditions. Improved
knowledge of these systems, in terms of function and molecular
organization, has confirmed their roles in the efficacy of older
medications. Medicinal chemistry has detected some newer
compounds that affect identifiedmolecular targets and additional
monoaminergic targets are still being investigated. Although
monoaminergic systems have a pivotal role in the effect of many
existing medicines, there is a need for further developments, as
additional targets have been identified that could be as interesting
as monoamines (Millan et al., 2015b).
Monoaminergic systems, involving dopamine (DA), serotonin
(5-HT), noradrenaline (NA) and histamine are involved in
virtually all cerebral functions and modification of their activity
has been identified in most, if not all, neuropsychiatric
and neurological diseases. Some of these diseases, including
schizophrenia, depression and Parkinson’s disease (PD) benefit
from monoaminergic-based treatments, but there is still scope
for therapeutic improvement. In spite of clear monoaminergic
disturbances in other devastating diseases, including Alzheimer’s
disease, addiction and epilepsy, no approved monoamine-based
treatments are yet available. The discovery of the most pertinent
drugs in numerous psychiatric diseases was serendipitous while
the causal implication of monoaminergic systems in several
diseases is still unclear. In this context, the identification of drug
targets as well as more detailed neuropharmacological analysis
should allow for the improvement of existing drugs.
The complexity of the organization of monoaminergic
systems in the brain limits the likelihood of drugs acting
on a single target to correct a disease selectively, although
recent examples suggest that this strategy might be worth
continuing (Meltzer and Roth, 2013). Moreover, specific targets
for a neurotransmitter are often distributed in numerous
neurobiological circuits so that a selective compound may
produce a plethora of distinct effects, some of which may
be undesirable. Such a situation may occur in the treatment
of diseases like schizophrenia where the use of DA receptor
antagonists is associated with undesirable side effects, as
discussed below. The complexity of these circuits may lead
to the proposed use of either agonists or antagonists for
correcting the same diseases (Di Giovanni and De Deurwaerdère,
2016). There is a growing body of evidence demonstrating
that most neuropsychiatric disorders are multifactorial and
that an action on a single target is elusive both in terms of
Abbreviations: COMT, catechol-O-methyl transferase; DA, dopamine; 5-HT,
serotonin; NA, noradrenaline; MAO, monoamine oxidase; MAO-I, monoamine
oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin
noradrenaline reuptake inhibitor; AD, Alzheimer’s disease; PD, Parkinson’s
disease; VTA, ventral tegmental area; SNc, substantia nigra pars compacta; LC,
locus coeruleus; L-DOPA, L-3,4-dihydroxyphenylalanine; AADC, aromatic L-
amino acid decarboxylase; DBH, dopamine β-hydroxylase; TPH, tryptophan
hydroxylase; VMAT2, vesicular monoamine transporter; SERT, 5-HT transporter;
DAT, DA transporter; NET, NA transporter; OCT, organic cation transporters;
PMAT, plasma membrane monoamine transporter; EPS, extrapyramidal side-
effects; TCA, tricyclic antidepressant; AChEI, acetylcholinesterase inhibitor; VAP-
1, vascular adhesion protein 1.
symptomatic and curative treatments (Millan et al., 2015a,b).
Increased understanding of the mechanisms involved in such
diseases led to the use of combinations of drugs targeting
distinct receptors/enzymes or to the development of multi-target
drugs. Finally, it is clear that the action on one target of one
monoaminergic system will have repercussion on the activity of
the other systems, which can affect the efficacy of medicines and
may also introduce unwanted side-effects.
Therapeutic approaches that target monoaminergic systems
are completely different and depend on the disease. The aim
of this review is to present the development of new chemical
compounds and therapeutic strategies aimed at modulating
monoaminergic function in various brain disorders. We used the
angle depicted in Figure 1 arbitrarily categorizing three groups
of diseases. Thus, after briefly presenting the physiology of the
four main monoamine systems in the brain, this review will
summarize past and current developments in the treatment
of neuropsychiatric diseases that have monoaminergic-based
medication (schizophrenia, depression, obesity) without a
clear pathophysiological picture. Thereafter, we will present
therapeutic strategies for brain diseases where the cause of the
disease has been identified but with distinct success regarding
the treatments and their amelioration (PD, drug addiction).
The review will finish by presenting some strategies aimed
at ameliorating the symptoms of brain diseases that still do
not benefit from monoaminergic-based treatments in spite of
the numerous evidence that it could be beneficial (epilepsy,
AD, and ischemic stroke). The choice has been also driven
by the involvement of the various researchers in the COST
action CM1103, which was dedicated to drug design in the
field of monoamines. The overall picture should give a clearer
indication of the neuropharmacological significance of targeting
monoaminergic systems in neuropsychiatric diseases and the
need for future research.
MONOAMINERGIC SYSTEMS IN THE
BRAIN
Pathways of monoaminergic systems project from the brainstem
to different brain areas and the spinal cord, and they
include dopaminergic neurons, located in the ventral tegmental
area (VTA) and the substantia nigra pars compacta (SNc),
noradrenergic neurons, arising from locus coeruleus (LC),
serotonergic neurons, originating from median and dorsal raphe
nuclei (Hale and Lowry, 2011) and histaminergic neurons
arriving from tuberomamillary nucleus of the hypothalamus
(Taylor, 1975). Figure 2 illustrates approximately the, still
limited, knowledge of the pharmacological and biochemical
identities for each of these systems. DA is a catecholamine
synthesized by the enzyme tyrosine hydroxylase (TH), which
catalyzes the conversion of the amino acid L-tyrosine to L-
3,4-dihydroxyphenylalanine (L-DOPA), and by the aromatic L-
amino acid decarboxylase (AADC) which converts L-DOPA into
DA (Cooper et al., 2003). DA can be metabolized by dopamine
β-hydroxylase (DBH) into NA. DBH is mainly present in vesicles
and can be found in the cytosol (Gagnon et al., 1976). 5-HT is
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FIGURE 1 | Relationships between brain diseases and monoamines. We artificially separate three groups of diseases. The first group is based on the discovery
of the involvement of monoamines in drug’s efficacy (the arrows go from the drugs to monoamines in a disease). The second group includes diseases where
monoamines have been causally involved in the disease, leading to development of monoaminergic drugs (L-DOPA for instance; the arrows go from the disease to the
drugs). The third group has no monoamine-based treatments implying an open research.
produced from L-tryptophan by tryptophan hydroxylase (TPH)
and AADC. Unlike in the case of the catecholamines and 5-
HT, the decarboxylase involved in the synthesis of histamine is
L-histidine decarboxylase (Taylor, 1975).
The degradation of biogenic amines is a complex mechanism
that is not fully understood because it involves several
enzymes and cell types. The monoamine oxidases (MAO)
are a family of flavin adenine dinucleotide (FAD)-containing
enzymes that catalyze the oxidative deamination of primary,
secondary or tertiary amines. They produce hydrogen peroxide,
ammonia and the corresponding aldehyde. There are two
isoforms of MAO present in mammals: MAO-A and MAO-
B, which share approximately 70% sequence identity and are
encoded by separate genes located on the X chromosome
(Youdim et al., 2006). The anatomical distribution of MAO
isoforms in human brains was confirmed by positron-emission
topography (PET) using intravenous 11C-labeled irreversible
inhibitors (Fowler et al., 1987). Autoradiographic and in situ
hybridization studies have revealed that histaminergic and
serotonergic neurons as well as astrocytes are rich in MAO-
B whereas catecholaminergic neurons mainly contain MAO-A
(Saura et al., 1992, 1996). DA, NA and 5-HT can be degraded
by MAO-A (Youdim et al., 2006; Finberg, 2014). The aldehyde
derivatives, which aremore toxic than the parent compounds, are
catabolized by aldehyde dehydrogenase/reductase (Eisenhofer
et al., 2004). MAO-B is involved in the glial metabolism
of catecholamines and can affect the metabolism of biogenic
amines in diverse conditions including PD (Youdim et al.,
2006; Riederer and Laux, 2011). It is also involved in the
metabolism of other amines, including 2-phenylethylamine and
N(tele)-methylhistamine.
Catechol-O-methyltransferase (COMT) can also metabolize
DA and NA (Eisenhofer et al., 2004). Two isoforms have been
described (soluble COMT, S-COMT; membrane-bound COMT,
MB-COMT) having different subcellular compartmentation.
In the brain, S-COMT is found in the cytosol of glial cells,
whereas MB-COMT is bound to the endoplasmic reticulum
and present in neurons. MB-COMT mainly inactivates
catecholamines and derivatives originating from DA and
NA neurotransmission, whereas S-COMT preferentially
transforms exogenous catecholamines (Myohanen et al., 2010;
Tammimäki et al., 2010). COMT is not present in DA terminals
(Schendzielorz et al., 2013), implying that glial cells or other
neurons reuptake extracellular DA in tissues where the clearance
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FIGURE 2 | Cellular and molecular organization of central monoaminergic systems. The figure depicts each monoamine system (dopamine, DA;
noradrenaline, NA; serotonin, 5-HT; histamine) the biosynthesis, metabolism, the receptors and transporters. The color is used to identify the proteins that are
selective for each system while the black color is used for non-specific proteins. The terminals of each monoaminergic neurons contact post-synaptic elements that
express a variety of receptors which are more or less specific for each monoamine. Autoreceptors can be located at terminals and cell bodies for most systems. In the
(Continued)
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FIGURE 2 | Continued
case of serotonergic cells, 5-HT1A autoreceptors are expressed at cell bodies and 5-HT1B autoreceptors are expressed at terminals The post-synaptic elements
(neurons, glial cells) also express enzymes involved in their metabolism (MAO-A/B, COMT, AADC) as well as non-specific transporters. Of note, the distribution of
MAO-B in the serotoninergic cells is rather located at the level of cell bodies. DBH is mainly expressed in vesicles of exocytosis in noradrenergic terminals. AADC,
aromatic L-amino acid decarboxylase; DBH, dopamine β-hydroxylase; TPH, tryptophan hydroxylase; VMAT2, vesicular monoamine transporter; SERT, 5-HT
transporter, DAT, DA transporter; NET, NA transporter; OCT, organic cation transporters; PMAT, plasma membrane monoamine transporter; HDC, L-histidine
decarboxylase; MAO, monoamine oxidase (A or B); COMT, catechol-O-methyl transferase.
of DA is low. COMT is also involved in the degradation of
metabolites generated by MAO activities. The final products
from these two distinct catabolic pathways is homovanillic
acid for DA metabolism and either vanillylmandelic acid or
a conjugated form of 3-methoxy-4-hydroxyphenylglycol for
NA metabolism (Eisenhofer et al., 2004). Histamine follows
distinct pathways. It is converted in the brain by histamine N-
methyltransferase to N(tele)-methylhistamine, which undergoes
degradation by MAO-B followed by the aldehyde oxidation
to N(tele)-methylimidazole acetic acid, while in periphery
histamine is degraded by diamine oxidase (Taylor, 1975;
Morisset et al., 2000).
Once synthesized, all monoamines are concentrated in the
vesicular compartment by the vesicular monoamine transporter
or VMAT2 (Wimalasena, 2011). Regarding the extracellular
space, various transporters are involved in the clearance of
monoamines. Three major classes of monoamine transporters,
5-HT transporter (SERT), DA transporter (DAT), and NA
transporter (NET), are responsible for the reuptake of 5-
HT, DA and NA, respectively, from the synaptic cleft back
to pre-synaptic neuron (Torres et al., 2003). Of note, the
reuptake of DA occurs physiologically through the NET in
extrastriatal tissues (Di Chiara et al., 1992). The reuptake
of these monoamines is not totally selective and there are
also several low affinity/high capacitance transporters including
the organic cation transporters (OCT1-3 subtypes) and the
plasma membrane monoamine transporter (PMAT) (Daws,
2009; Hensler et al., 2013; De Deurwaerdère et al., 2016). These
systems, which are expressed by glial cells and other types
of neurons, are involved in the reuptake of histamine (no
preferential transporter) and the other monoamines. Thus, while
the first step of synthesis can be selective, most of the other
steps are overlapping and the catabolism involves cells other than
monoaminergic neurons (Figure 2). Furthermore, the enzymes
of biogenic amine catabolism are involved in several additional
processes.
The main selectivity regarding these systems, although limited
to some extent, is conferred by the receptors; two families for
DA (D1-like including D1 and D5R and D2-like including D2L,
D2S, D3, D4 receptor subtypes) (Emilien et al., 1999; Beaulieu
and Gainetdinov, 2011), three families also for NA (α1a,b,d or
α2a−d receptor subtypes, and β receptor subtypes including β1−3)
(Andersson, 1980; Ahles and Engelhardt, 2014; Ghanemi andHu,
2015), four for histamine (H1−4) (Panula et al., 2015) and seven
for 5-HT (5-HT1−7) (Barnes and Sharp, 1999; Hoyer et al., 2002).
They are mostly G-protein-coupled receptors (GPCR), except for
the 5-HT3 receptor subtypes which are channel receptors. The
cerebral distribution is distinct for each receptor. The differential
distribution in some brain regions for a subtype can be a hint with
regards to its participation in some specific functions. Details
related to brain expression of monoamine receptors are found in
the above-cited authoritative reviews. In any case, most of them
are expressed in several neurobiological networks. Moreover,
several subtypes may directly, as autoreceptors (see below),
or indirectly modify the activity of monoaminergic neurons,
thereby altering neurobiological networks beyond their specific
distribution.
Each monoaminergic neuronal system has its own
autoreceptor(s). Thus, adrenergic cells express the α2c receptor
while histaminergic neurons express H3 receptors. Dopaminergic
and serotonergic neurons express D2/D3 receptors and 5-HT1A,
5-HT1B/1D and 5-HT2B receptors, respectively. The function of
these autoreceptors located at both cell bodies and/or neuron
terminals is usually to inhibit the electrical activity, excitability,
synthesis and/or release. They also regulate the activity of the
transporters presumably via intracellular signaling pathways. As
illustrated in Figure 2, these autoreceptors are also expressed by
other cell types (heteroreceptors).
The last point to consider when dealing with
neuropharmacology of monoaminergic systems is that, either by
acting on non-selective enzymes such as MAO, or by selectively
targeting one receptor, the biological responses likely involve all
systems due to their interaction throughout the brain (Fitoussi
et al., 2013; Hensler et al., 2013). The complex interaction
between these systems overwhelms the single target and the
integrative views of the newer monoaminergic treatments
must clearly include this dimension (De Deurwaerdère and Di
Giovanni, 2016).
FROM THE DRUGS TO MONOAMINES
Treatments of Schizophrenia
Historical Perspectives
It is logical to start the overview of the monoaminergic potentials
in psychiatry by the discovery of neuroleptic drugs (antipsychotic
drugs), which may be considered as the birth of biological
psychiatry. Schizophrenia is a complex neuropsychiatric disorder
with high prevalence (Owen et al., 2016). In the early 1950s,
chlorpromazine was initially used by the French physicians
Laborit and Charpentier for its antihistaminic properties, to calm
down patients before anesthesia. The effect of chlorpromazine
was spectacular and it was transposed successfully to the
treatment of schizophrenia by Deniker and Delay (López-Muñoz
et al., 2005). Other drugs from different chemical classes were
found to mimic the antipsychotic action of chlorpromazine, but
it was several years before the understanding that dopaminergic
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system could be involved (Carlsson and Lindqvist, 1963), and
that the DA (D2) receptor subtype was a common target of
all antipsychotic drugs (Seeman et al., 1975, 1976). Nowadays,
central D2 receptors, among other receptor types, remain an
essential target in drug design of newer antipsychotic drugs
(Butini et al., 2016).
Mechanisms of Action of Antipsychotic Drugs
All antipsychotic drugs block the D2 receptor subtype and the
antipsychotic efficacy depends on the proportion of occupied
D2 receptors, which is directly related to the affinity of the
compound at D2 receptor and the free plasma concentration
of the antipsychotic drug. Most of these drugs including
chlorpromazine or haloperidol are efficacious against positive
symptoms of schizophrenia such as delusion, paranoia or
hallucinations. Their therapeutic benefit is assumed to be
related to the blockade of D2 receptors in the ventral striatum
(nucleus accumbens). On the other hand, these compounds
are not efficacious against the negative symptoms which may
even aggravate (Millan et al., 2014; Remington et al., 2016).
These drugs also induce several serious side-effects, either
due to their off-targets including H1, α2, muscarinic2 (M2)
receptor antagonist properties, or to chronic central D2 receptor
blockade. Notably the extrapyramidal side-effects (EPS) include
parkinsonism, akathisia, dystonia and tardive dyskinesia (Ebadi
and Srinivasan, 1995).
Although clozapine is more efficacious against negative and
cognitive symptoms than other antipsychotic drugs and has fewer
EPS (Ashby and Wang, 1996), its clinical use was discontinued
due to its propensity to induce agranulocytosis. However, it was
subsequently reintroduced if carefully monitored (Deutch et al.,
1991; Ashby and Wang, 1996). The peculiar clinical responses
gave rise to the concept of the typical and atypical antipsychotic
drugs, the latter inducing less EPS and vegetative effects (Meltzer,
1993, 1999). Studies of the pharmacological behavior of drugs
like clozapine or risperidone led to the proposal that the atypical
profile corresponds to a higher affinity of the drug toward 5-
HT2 (i.e., 5-HT2A) vs. D2 receptor subtypes (Meltzer et al.,
1989a,b). This pharmacological constraint has been added to the
D2 receptor target in the selection of drugs possibly exhibiting an
atypical antipsychotic profile. Drugs like olanzapine, quetiapine,
ziprasidone and more recently brexpiprazole are representatives
of this class (Table 1). These newer antipsychotic drugs have
lower propensity to induce EPS, but another concern emerges
regarding the development of metabolic side effects such as
weight excess. It is possible that their antagonist/inverse agonist
profile at 5-HT2C receptors in addition to the H1 receptor
antagonism participate to the development of increased body
weight and obesity side effect (see below) (Table 1).
The superiority of clozapine in terms of low incidence of EPS
has been also related to its low affinity at D2 receptors, implying a
fast dissociation from the receptor and avoiding unsurmountable
D2 receptor blockade, either acutely or chronically (Kapur and
Seeman, 2001). This property has not been verified for all
antipsychotics but it introduces the notion that antipsychotic
drugs could correct rather than block central DA transmission.
Aripiprazole brexpiprazole or cariprazine display partial agonist
activities at some signaling pathways connected to D2 receptors
(Kiss et al., 2010; Citrome, 2013, 2015). In spite of the high
occupancy of D2 receptors in vivo presumably overwhelming
the 80% threshold occupancy, these partial or biased agonists do
not induce catalepsy in rats and induce fewer EPS in humans
compared to typical neuroleptics (Citrome, 2015).
Questions and Directions
There are several outstanding questions for neuropharmacology.
In spite of the availability of antipsychotic drugs minimizing the
occurrence of EPS, abnormal motor responses are still present
with some of these medications.
(i) The reason why 5-HT2A receptor antagonism has beneficial
effects is still not fully understood with respect to the
lower EPS and the involvement of motor part of the basal
ganglia. There are reasonable amounts of data showing
that the impact of D2 receptor blockade in the presence
of 5-HT2A receptor antagonism would be reinforced in
the mesolimbic system and conversely dampened in the
mesocortical system (Meltzer and Huang, 2008). Indeed,
5-HT2A receptor antagonists enhance DA release induced
by D2 receptor blockade in the cortex. A similar property
has been observed with 5-HT1A receptor agonism (Meltzer
and Massey, 2011; Hensler et al., 2013; Schreiber and
Newman-Tancredi, 2014). This may explain the fact that
antipsychotic drugs like cariprazine, with low affinity for 5-
HT2A receptor and moderate to high affinity for 5-HT1A
receptors, display atypical antipsychotic drug profiles in
the clinic (Kiss et al., 2010; De Deurwaerdère, 2016). The
favorable profile regarding motor parts of the basal ganglia
is not likely to be related to a putative disinhibitory action
of 5-HT2 receptor blockade on DA neuron activity, as had
been previously speculated (Kapur and Remington, 1996;
De Deurwaerdère and Di Giovanni, 2016). Rather, their
cortical effects could have beneficial effects on cognitive
symptoms of the disease that are, in part, independent
from D2 receptor blockade. The categorization in typical
vs. atypical antipsychotics is not always clear in considering
only the binding profiles (Table 1).
(ii) The negative symptoms remain one of the most difficult
challenges in the treatment of schizophrenia (Millan
et al., 2014; Remington et al., 2016). Interestingly,
neuropsychopharmacological analysis tends to dissociate
various symptoms of schizophrenia which could have
distinct etiology (Buckley et al., 2009). Acting on these
distinct dimensions implies a combination of selective drugs
or the use of multi-target medicines (Butini et al., 2016), and
animal models adapted for the different symptoms (Millan
et al., 2014). This implies, in turn, an extensive preclinical
evaluation for testing the suitability of any new compound
(Millan et al., 2015b; De Deurwaerdère, 2016; Di Giovanni
and De Deurwaerdère, 2016). Some of the most advanced
treatments focus on the following targets (Table 1): D2
receptor antagonism regarding the positive symptoms,
5-HT1A receptor agonism/5-HT2A receptor antagonism
and/or increase in cortical acetylcholine release for the
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TABLE 1 | Receptor-binding affinities of typical and atypical antipsychotic drugs.
Antipsychotics D2 D3 5-HT1A 5-HT2A Other targets*
TYPICAL ANTIPSYCHOTICS
Haloperidol 8.84 8.56 6.29 7.28 D4 (8.83); α1A (7.9); σ1 (8.52)
flupentixol 9.46 8.76 5.1 7.06 D1 (8.46); H1 (9.07)
Thioridazine 9.4 8.82 6.84 7.56 α1A (8.5); α1B (8.62); M1 (7.89); M5 (7.9); H1 (7.78)
Pimozide 9.48 9.6 6.19 7.32 5-HT7 (9.3); D4 (8.74)
Perphenazine 8.47 9.89 6.38 8.25 5-HT6 (7.77); 5-HT7 (7.64); D1 (7.52); D4 (7.77); α1A (8); H1 (8.1); σ1 (7.73)
Loxapine 7.96 7.71 5.61 8.18 5-HT2C (7.88); 5-HT6 (7.51); 5-HT7 (7.06); D1 (7.27); D4 (8.08); D5 (7.12); α1A (7.51); α1B
(7.28); α2A (6.82); α2B (6.97); α2C (7.1); M1 (6.92); H1 (8.3)
ATYPICAL ANTIPSYCHOTICS
Clozapine 6.87 6.66 7.06 8.39 5-HT1B (6.28)b; 5-HT2B (8.79); 5-HT2C (8.56 - IA); 5-HT3 (6.62); 5-HT6 (7.87); 5-HT7
(7.75); D1 (7.64); D4 (7.33); D5 (6.63); α1A (8.79); α1B (8.15); α2A (7.43); α2B (7.58); α2C
(8.22); M1 (8.21); M2 (7.44); M3 (7.72); M4 (7.81); M5 (7.81); H1(8.95); H2 (6.82); H4 (6.18)
Risperidone 8.21 8.16 6.75 9.69 5-HT1B (7.83); 5-HT1D (7.07); 5-HT2B (7.8); 5-HT2C (8.17); 5-HT7 (8.18); D4 (8.21); D5
(7.8); α1A (8.3); α1B (8.04); α2A (7.78); α2C (8.89); H1 (7.7)
Olanzapine 7.67 7.46 5.82 8.88 5-HT2B (8.41); 5-HT2C (8.41); 5-HT3 (6.69); 5-HT6 (8.09); 5-HT7 (6.98); D4 (7.75); D5
(7.04); α1A (6.95); α1B (6.58); α2A (6.5); α2B (7.09); α2C (7.54); M1 (7.58); M2 (7.2); M3
(7.28); M4 (7.61); M5 (8.12); H1 (8.66); H2 (7.36)
Ziprasidone 8.09 8.35 9.01 9.51 5-HT1B (8.4); 5-HT1D (8.64); 5-HT2B (9.08); 5-HT2C (9.01); 5-HT6 (7.21); 5-HT7 (8.22);
D1 (8.45); D4 (7.33); α1A (7.74); H1 (7.2); SERT (7.26); NET (7.32)
Quetiapine 6.38 6.41 6.78 6.81 5-HT2B (7.33); 5-HT2C (5.98); 5-HT6 (6.02); 5-HT7 (6.51); D1 (6.71); D4 (5.85); D5 (7.8);
α1A (7.66); α1B (7.84); α2A (5.44); α2C (7.65); H1 (8.16); H2 (7.38); M1 (489); M3 (5.79)
Brexpiprazole 9.48 8.9 9.21 9.67 α1A (8.42); α1B (9.23); α1D (8.58); α2C (9.77); 5-HT2B (8.72); 5-HT7 (8.43)
Aripiprazole 8.9 8.85 8.57 8.02 5-HT2B (9.59)
Cariprazine 9.31 10.07 8.59 7.73 5-HT2B (9.24)
Amisulpiride 8.89 8.62 5.8 5.08 5-HT2B (7.89); 5-HT7 (7.94)
Blonaserin 9.84 9.3 6.09 9.09
The pKi values shown are taken from several sources, including mean values from the PDSP Ki database (Roth and Driscol, 2016). The values for the receptors: D2, D3, 5-HT1A,
5-HT2A, 5-HT2B, 5-HT2C with atypical antipsychotics were from Leggio et al. (2016) or Citrome (2015). The colors indicate: Blue, drugs with higher affinity for D2 receptors; Orange,
drugs with a 5-HT/DA binding profile; Violet, drugs with a D2/3 effects; Green, drugs with partial agonist activities at D2 receptors. 5-HT2B receptors are a recurrent target of several
atypical antipsychotic drugs. Conversely, none of the agents presented above bind at 5-HT4 receptors. M1-M5, muscarinic receptors; σ1, sigma 1 receptors. *in the range of 1 order
of magnitude compared to the affinity at D2 receptors.
cognitive symptoms, and perhaps D3 receptor antagonism
for the negative symptoms (Figure 3).
(iii) The pharmacological analysis of the newer antipsychotic
drugs has led to consideration of other targets including
5-HT6, 5-HT7 receptors (Meltzer and Huang, 2008; Mauri
et al., 2014) or the intriguing 5-HT2B receptors (Devroye
et al., 2016) (Table 1). Since the interaction between
neurotransmitter systems is extremely complex, actions
directed to some targets (e.g., D2 receptors) might unmask
a deleterious involvement of other circuits. For instance,
while the 5-HT2C receptor blockade has not been shown
to be primarily involved in the antipsychotic drug action,
its blockade might be necessary to limit the occurrence
of EPS induced by typical neuroleptics (Richtand et al.,
2008). The neurobiological process underlying a deleterious
involvement of 5-HT2C receptors that follows D2 receptor
blockade is not well understood (De Deurwaerdère et al.,
2013). Because of the frequency of co-morbid diseases
including mania, anxiety or depression in schizophrenic
patients, this analysis further indicated the prescription of
other medicines in addition to antipsychotic drugs (Buckley
et al., 2009). Most available antipsychotic drugs have
a complex pharmacological profile including adrenergic,
muscarinic and histaminergic sites and most of them,
especially the newer ones, are also developed for the
treatment of bipolar disorder and major depression.
(iv) Very few strategies have tried to avoid the D2 receptor
target because most, if not all trials targeting a single site
other than D2 receptors failed to reach clinical significance
(Deutch et al., 1991; Ashby and Wang, 1996; Meltzer
and Massey, 2011). Recently, the 5-HT2C receptor agonist
vabicanserin has been tested as a monotherapy in the
treatment of schizophrenia. This was justified as the 5-
HT2C receptor inhibits DA release, at least in the nucleus
accumbens, and its preferential agonists are efficacious in
several preclinical models of schizophrenia (Rosenzweig-
Lipson et al., 2012). Although the strategy of stimulating 5-
HT2C receptors should be taken with caution (Di Giovanni
and De Deurwaerdère, 2016), it protects at least from the
development of obesity due to its anorexigenic property
and would be less prone to promoting EPS. Although
having an antipsychotic profile, vabicanserin was not more
efficacious than risperidone at primary end point, and
its development was discontinued (Shen et al., 2014).
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FIGURE 3 | Design of antipsychotic drugs. The elaboration of antipsychotic drugs pays attention to the positive symptoms, negative symptoms, cognitive deficits
and extrapyramidal side effects. The D2 receptor subtype is the main target for the positive symptoms. The 5-HT2C receptor is an example of preclinical research
target offering another possibility based on the reduction of DA neuron activity. Different targets are proposed to limit the other deficits or to avoid motor side-effects
including the 5-HT2A, 5-HT1A or D3 receptor subtypes. Nowadays, one of the main difficulties is to address the negative symptoms and some preclinical studies
suggest beneficial effects of targeting the D3 receptor subtypes.
Nonetheless, vabicanserin might represent a change of
strategy regarding the development of newer antipsychotics,
focusing on the activity of the monoaminergic systems
rather than on a single site.
Conclusion
After having isolated one target of antipsychotic drugs, namely
the D2 receptor subtype, the search for additional targets is
essential for better intervention of the full spectrum of symptoms
in schizophrenia. This cannot be achieved by acting on a single
target, necessitating the use of a cocktail of drugs or multi-
targeted compounds (Figure 3). Themethodological approach to
developing antipsychotic drugs is still conditioned by molecular
pharmacology, although new developments in connectomics
should prove valuable in the future (Fornito and Bullmore, 2015).
Treatments of Depression
Historical Perspectives of Antidepressant Drugs
Major depression is a severe, highly disabling, psychiatric
disorder which is becoming a leading cause of global
disease burden, with a growing prevalence of 3–17% in
adults and 2.8–5.6% in adolescents (Gururajan et al., 2016;
Rantamaki and Yalcin, 2016). Its multifaceted, but poorly
understood etiology involves complex interactions between
different biological (genetic, epigenetic, neuroendocrine and
neuroimmune), psychosocial (personality traits), developmental
and environmental (exposure to early life stress) factors.
In the 1950s began a new era in the field of
psychopharmacology with the clinical introduction of two
antidepressants: iproniazid and imipramine (López-Muñoz
and Alamo, 2009). Iproniazid, originally developed for anti-
tuberculous purposes, was characterized as MAO inhibitor
(MAO-I) by Zeller and Barsky (1952). Its administration
improved mood in patients and it was shown to lead to an
increase in the brain levels of 5-HT in rodents (Udenfriend et al.,
1957). The discovery of the antidepressant effects of iproniazid
laid the path for development of more effective MAOIs such as
phenelzine, tranylcypromine, isocarboxazid, and other hydrazine
and indole derivates (Ban, 2001). The compound, now known
as imipramine, was presented by Kuhn in 1957 as the first
representative of the tricyclic antidepressants (TCAs) (Brown
and Rosdolsky, 2015). In the period between 1960 and 1979,
many different TCAs were developed, including amitriptyline,
nortriptyline, desipramine, trimipramine, protryptyline,
iprindol, dothiepin and clomipramine (Fangmann et al., 2008;
López-Muñoz and Alamo, 2009). First tricyclic antidepressants
were shown to inhibit the uptake of NA. The modification of
the basic dibenzazepine structure of imipramine resulted in the
discovery of new cyclic antidepressants during 1970s, including
maprotiline and mianserine. The significant therapeutic effects
of MAO-Is and TCAs, stimulated an increased interest in the
role of monoaminergic system in the etiology of depression.
Fluoxetine, the first selective serotonin reuptake inhibitor
(SSRI), came out in 1975 (Wong et al., 1975) and was introduced
in 1987. Its unique properties and appropriate clinical efficacy
established the SERT as an important target in the treatment
of depression (Perez-Caballero et al., 2014). Fluoxetine is, in
fact, not highly selective toward the SERT whereas citalopram,
escitalopram, fluvoxamine, paroxetine or sertraline block the
SERT more selectively (Thomas et al., 1987; Jacquot et al., 2007).
Their efficacy is similar to TCAs but SSRIs generally have lower
toxicity in comparison with MAO-Is and TCAs.
Mechanisms of Action of Antidepressant Drugs
The neurobiological basis of depression is not fully understood
although the monoaminergic theory of depression stipulates
5-HT and NA extracellular deficits in different brain regions.
This remains far from to be clear however, except in
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major depression with suicidal behavior where the levels of
tissue 5-HT were found lower compared to levels in age-
matched controls (Delgado and Moreno, 2000). In animals,
the destruction of either 5-HT or NA systems, or both, does
not trigger depressive-like symptoms in some behavioral tests
(Page et al., 1999; Cryan et al., 2002, 2005; Delaville et al.,
2012). On the other hand, the enhancement of 5-HT and
NA neurotransmission with some antidepressant medication
results in the improvement of the common symptoms of the
disease.
Studies with SSRI and other blockers of monoaminergic
reuptake sites indicate that the efficacy of antidepressant drugs
entails at least three sequential steps. (1) The blockade of SERT
at the level of 5-HT cell bodies enhances somatodendritic 5-HT
extracellular levels (Bel and Artigas, 1992; Invernizzi et al., 1992),
thereby activating 5-HT1A autoreceptors and reducing the firing
rate of 5-HT neurons (Blier and de Montigny, 1990; Adell et al.,
1993; Guiard et al., 2005). The blockade of SERT at terminals of 5-
HT neurons enhances extracellular levels of 5-HT but this effect
is considerably dampened by the decrease in 5-HT neuron firing
rate and the stimulation of 5-HT1B autoreceptors located at 5-
HT terminals (Invernizzi et al., 1992; Gardier et al., 2003). (2) The
desensitization of somatodendritic 5-HT1A receptors in the raphe
nuclei upon subchronic administration of SSRI, with the main
consequence of magnifying the effects of the SERT blockade on
the extracellular levels of 5-HT (Invernizzi et al., 1996; Piñeyro
and Blier, 1999). (3) The final step involves modification of 5-
HT receptors at 5-HT receptive cells including 5-HT1A, 5-HT2A
or 5-HT2C receptors (Artigas et al., 2002; Artigas, 2013). These
sequential steps take time which may account for the delay
between start of treatment with antidepressant drug and clinical
effect.
The interaction between 5-HT and NA systems is evident
in the mechanism of action of TCAs because most TCAs
have a better affinity for the NET compared to the SERT.
Numerous studies have provided evidence that α1 and α2
receptors exerted complex interactions on 5-HT neurons, α1
receptor being excitatory. Conversely, 5-HT at least via 5-
HT2A receptors inhibits the activity of NA neurons whereas the
desensitization of 5-HT2A receptors, also occurring after SSRI,
allows for an increase in central NA tone (Piñeyro and Blier,
1999; Hamon and Blier, 2013). Thus, the interaction between
the 5-HT and the NA has a pivotal role in the mechanism
of action of drugs targeting monoaminergic neurons terminal
activity including TCAs, SSRI and MAO-I. Other antidepressant
drugs target 5-HT and/or NA receptors (see below), but their
mechanisms of action are less well understood. Through the
interaction between monoaminergic systems (Hamon and Blier,
2013), DA changes are indirectly involved in the mechanism
of action of antidepressants. The DA system is usually not
directly targeted in the treatment of depression (nonetheless,
see below with the introduction of antipsychotics in major
depression).
Amelioration of Antidepressant Drugs Actions
In the last 20 years two main problems with antidepressant
treatment have emerged, including a poor or partial response,
i.e., a large proportion of patients not responding well to
the therapy (Gumnick and Nemeroff, 2000), and the delay
of action of antidepressant drugs usually reached after 2–
3 weeks of treatment. The partial response of antidepressant
drugs has led to the introduction of new and more effective
antidepressants like venlafaxine, which inhibits the reuptake of
5-HT and NA (NSRI), and mirtazapine, which acts primarily as
an antagonist of presynaptic α2-adrenoreceptors (Artigas et al.,
2002). A meta-analysis assessed the effects of 12 new-generation
antidepressants and showed that mirtazapine, venlafaxine and
two SSRIs, escitalopram and sertraline, were more efficacious
than other SSRIs (fluoxetine, fluvoxamine and paroxetine), the
NSRI duloxetine and the selective NA reuptake inhibitor (SNRI)
reboxetine (Cipriani et al., 2009).
The antidepressant effect of MAO-Is is dependent on
inhibition of MAO-A but irreversible inhibition of that
isoenzyme resulted in adverse hypertensive reactions with foods
containing tyramine called “the cheese effect.” To avoid this
adverse event, a new strategy for the treatment of depression
was presented in the form of reversible inhibitors of MAO-A
(RIMA), such as moclobemide (Haefely et al., 1992), brofaromine
(Davidson, 2003), and befloxatone (Curet et al., 1998). However,
the use of MAO-Is today is mostly limited for treating patients
with atypical depression, bipolar depression, treatment-resistant
depression, or hyperserotonergic responses with SSRIs. In 2009,
agomelatine, the first antidepressant that mediates its activity via
the melatonergic pathway was approved (San and Arranz, 2008;
Millan et al., 2010; Racagni et al., 2011). This antidepressant acts
as an antagonist at 5-HT2C receptors and agonist at melatonergic
MT1 and MT2 receptors (Millan et al., 2010). In comparison
with other standard SSRIs and SNRIs, agomelatine showed
similar or even favorable efficacy and tolerability (Kasper et al.,
2013). In addition to agomelatine, several other 5-HT2C agents
have been reported to display strong anxiolytic/antidepressant
properties in animal models and clinical studies (Millan, 2005,
2006; Millan et al., 2005; Di Giovanni and De Deurwaerdère,
2016). A summary of these evolutions has been indicated in the
Table 2.
The second problem associated with antidepressant treatment
is the delay of action of the drugs. Knowledge of the mechanism
of action of SSRIs resulted in the proposal to reduce the
delay of action by blocking 5-HT1A/1B autoreceptors, thereby
lessening the time period needed to produce the massive increase
in 5-HT levels at the synaptic cleft (Artigas et al., 1996).
However, since the efficacy of SSRI is also associated with
postsynaptic 5-HT1A receptors (Blier et al., 1990), which are not
desensitized and are required for the benefit of SSRIs, such a
blockade might be expected to be counterproductive. Similar
augmentation can be achieved by concomitantly blocking 5-
HT2C receptors, which indirectly inhibit 5-HT neuronal activity
(Cremers et al., 2004, 2007). Clinical trials involving this
approach are underway (see Di Giovanni and De Deurwaerdère,
2016). Another monoaminergic possibility to obtain a fast onset
of the antidepressant effect is the use of 5-HT4 receptor agonists.
These compounds act directly on 5-HT receptive fields in the
hippocampus or the cortex and indirectly stimulate 5-HT release.
Their pro-cognitive and anxiolytic effects have raised some
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TABLE 2 | Pharmacological targets of lead and newer antidepressant drugs from lead compounds.
Lead compounds Mechanisms of action New compounds in clinic Main targets
Imipramine, Fluoxetine 5-HT/NA interaction mostly via blockade
of SERT and/or NET
+
Alteration of monoamine targets and
function
SSRI (Escitalopram, Citalopram, Paroxetine...)
NSRI (Duoxetine, Venlafaxine)
SNRI (Reboxetine)
Multi-target drugs (Vortioxetine)
SERT
SERT and NET
NET
SERT/5-HT receptors
Iproniazid 5-HT/NA interaction mostly via inhibition of Moclobemide MAO-A (reversible inhibitor)
MAO-A/B (irreversible) Agomelatine MT1/MT2 agonist/5-HT2C antagonist
Lead antidepressant drugs and their proposed mechanisms of action as well as newer drugs in clinical use that retain some of their targets. Agomelatine is included, although its 5-HT2C
receptor antagonist action was not directly based on a lead drug (Di Giovanni and De Deurwaerdère, 2016).
interest for the treatment of depression (Lucas and Debonnel,
2002; Lucas et al., 2007; Mendez-David et al., 2014).
Future Directions
Newer antidepressants have been developed with more
complex pharmacological profile such as vortioxetine (Sanchez
et al., 2015). This compound blocks the SERT as well
multiple 5-HT receptors (Sanchez et al., 2015; Sagud et al.,
2016). This effect is in line with studies reporting that the
combination of antidepressants with atypical antipsychotic
drugs (olanzapine, risperidone, quetiapine, aripiprazole,
paliperidone, ziprazidone, and amisulpride), can boost the
effectiveness of depression treatment (Berman et al., 2007;
Thase et al., 2007; Bauer et al., 2009; Han et al., 2013). Thus,
the monoaminergic system remains an important field for
producing newer antidepressant drugs involving refined
strategies (Hamon and Blier, 2013; Artigas, 2015). Recently,
there has been a growing interest in neuronal plasticity,
cholinergic, GABAergic and glutamate neurotransmission,
stress and HPA axis, reward system and neuroinflammation
as potential underlying mechanisms of depression that go
somehow beyond monoaminergic strategies (Artigas, 2015;
Dale et al., 2015; Millan et al., 2015a). However, the complexity
of the system is such that monoaminergic antidepressant
drugs may act on different neurobiological circuits and
molecular mechanisms, which might be more important
targets.
Obesity and Energy Balance
Historical Perspective
The neurobiological networks involved in food intake and
energy balance have been the subjects of many recent
studies, in view of the growing evidence for a worldwide
problem of obesity. The first anti-obesity drug targeting amine
neurotransmitter signaling was amphetamine. Amphetamine, α-
methylphenethylamine, member of β-phenylethylamine group of
drugs, was synthesized to substitute for ephedrine. Animal and
human studies showed that this compound can produce arousal
and insomnia. Racemic α-methylphenethylamine, registered by
SK&F under the name Benzedrine R©, was introduced in 1935
to treat narcolepsy and was also employed for mild depression,
post-encephalitic parkinsonism, schizophrenia, alcoholism and
other disorders (see (Bett, 1946)). In 1937, SK&F marketed
Dexedrine (d-amphetamine), the more potent of the two
isomers which produced euphoria, excitability, hyperactivity
and restlessness with hyperthermia. The quick loss of weight
in obese subjects treated against narcolepsy with Benzedrine
aroused the interest in the use of the sympathomimetics
as anti-obese medicines. A clinical study on 162 patients
treated with d-amphetamine, which had been performed on
a smaller number of subjects, supported its usefulness as
appetite depressant (Hawirko and Sprague, 1946). However, d-
amphetamine produces addiction (Kiloh and Brandon, 1962).
To decrease addictive potential, substituted amphetamines such
as phenyl-tertiary-butylamine, phentermine, and fenfluramine
(3-trifluoromethyl-N-ethylamphetamine) were synthesized and
were approved by FDA between 1959 and 1973 for weight
loss.
Mechanism of Action
The hypothalamus is a key structure involved in food intake
regulation and energy balance. It receives monoaminergic
terminals from several different sources and the roles of
the monoamines appear to be different: 5-HT and histamine
participate as a satiety factors; DA acts as the main signaling
molecule in a reward system, and NA tends to enhance energy
expenditure. Animal studies have shown that phenyl-tertiary-
butylamine, phentermine, and fenfluramine cause the release
of amines from the nerve terminals as well as inhibiting their
uptake. While d-amphetamine has higher affinities for DAT
and NET than SERT, fenfluramine has a higher affinity for
SERT (Garattini, 1995; Kuczenski et al., 1995). In rat, both
peripheral and central mechanisms of fenfluramine action have
been implicated (Carruba et al., 1986).
Studies with selective ligands of 5-HT receptors in vivo have
shown that hypophagic effect triggered by d-fenfluramine and its
metabolite d-norfenfluramine was mediated by 5-HT acting on
5-HT2C receptors (Vickers et al., 2001) (Table 3). Combination
of phentermine and fenfluramine, i.e., “Phen-Fen,” enables the
therapeutically effective dose of appetite suppressants to be
decreased. However, the heart valve disease related to a 5-HT2B
receptor agonism action and pulmonary hypertension (Vivero
et al., 1998; Palmieri et al., 2002) caused the withdrawal of
fenfluramine and dexfenfluramine from the U.S. market in 1997.
Later meta-analysis of the observational studies indicated that
fenfluramine-associated valvular regurgitation was less common
that assumed, but still present in 1 out of 8 patients treated
for >90 days (Sachdev et al., 2002). The next anti-obesity drug
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TABLE 3 | Anti-obesity drugs and mechanisms.
Lead compounds Mechanisms of action New compounds in clinic Main targets
Amphetamine DAT, NET and release of catecholamines Sibutramine
Reboxetine
NET/SERT (withdrawn)
NET
d-fenfluramine 5-HT release and indirect 5-HT2C agonism Lorcaserin Preferential 5-HT2C receptor agonist
Antipsychotic drugs Obesity as side effects via H1 receptor antagonism Cariprazine, Brexpiprazole,
Aripiprazole
Weak to no affinity toward H1 (even
5-HT2C) receptors (Table 1)
Lead compounds in the field of anti-obesity drugs and their proposed mechanisms of action are shown, together with newer drugs with similar actions. Amphetamine enhances
catecholamines release through its action on DAT and NET, which led to the development of drugs that enhanced NA release. D-fenfluramine, chemically derived from amphetamine,
loses affinities for DAT and NET in relation to SERT. Conversely, antipsychotic drugs induced weigh gain that has been corrected in newer compounds.
sibutramine (Luque and Rey, 1999), originally developed as an
antidepressant, is a potent SERT and NET inhibitor in vivo
(Luscombe et al., 1990). Animal studies on its mechanisms
of action pointed to the activation of β1-adrenoceptors, 5-
HT2A/2C receptors and α1-adrenoceptors (Jackson et al., 1997).
The compound has been shown in clinical trial to be an
efficient therapeutic, although the patients who stopped using
the drug quickly regained weight (James et al., 2000), as
observed for the substituted amphetamines (Vivero et al., 1998).
Sibutramine, having antiatherogenic activities (improvement
of insulin resistance, glucose metabolism, dyslipidemia, and
inflammation) concomitantly induces a moderate increase in
heart rate, a slight increase in blood pressure and may
also prolong the QT interval, inducing arrhythmias (Scheen,
2010). Because the hazard ratio for cardiovascular events was
significantly increased in sibutramine treated patients, the drug
was withdrawn from markets in 2010 (Haslam, 2016).
In 2012, a novel drug, lorcaserin, was approved by FDA
for the treatment of obesity. It is a 5-HT2C receptor agonist
that is appetite suppressing while free of cardiovascular effects
(Gustafson et al., 2013). It has about 15 and 100 times higher
affinity for 5-HT2C than for 5-HT2A and 5-HT2B receptor
subtypes. This drug stimulates the 5-HT2C receptors located on
proopiomelanocortin neurons in the arcuate nucleus resulting
in the release of α-melanocortin-stimulating hormone, which
suppresses appetite by acting on melanocortin-4-receptors in the
paraventricular nucleus (Voigt and Fink, 2015). It probably has
other actions in the brain including the decrease in DA release
in the nucleus accumbens, dampening goal-directed behavior
(Higgins and Fletcher, 2015; Di Giovanni and De Deurwaerdère,
2016).
Histamine and Obesity
The H1 receptor antagonist component of various medications
including antipsychotics is suspected to increase body weight
(Kroeze et al., 2003; Ratliff et al., 2010). In addition, recent
work indicates also that cerebral histaminergic system
mediates the anorexic effects of oleoylethanol amide, an
endogenous agonist at peroxisome proliferator-activated
receptor alpha (PPAR-α) (Provensi et al., 2014). Experimental
and preclinical studies employing different animal models
have convincingly shown that H1 and H3 receptors play
an important role in energy balance and body weight gain,
H1 receptor agonists and H3 receptor antagonist/inverse
agonists being anorexic drugs (Clineschmidt and Lotti, 1973;
Lecklin et al., 1998; Masaki et al., 2004; Provensi et al., 2014,
2016).
Although much attempt has been done in developing
histaminergic agents as anti-obesity treatment, no recent drug
with a histaminergic profile reached clinics (Esbenshade et al.,
2006; Provensi et al., 2016). Betahistine, registered in Europe in
1970 for the management of vertigo and vestibular pathologies,
could be used to achieve anti-obesity action in some conditions
(Provensi et al., 2016). This drug, combining weak agonism
at H1 receptor and inverse agonism at H3 receptor, stimulates
histamine synthesis and release in tuberomammillary nuclei
of the posterior hypothalamus (Arrang et al., 1985; Tighilet
et al., 2002; Gbahou et al., 2010). On the one hand, only
10% of 281 obese participating to a multicenter randomized
placebo controlled trial positively responded to the 12 weeks
therapy with betahistine (Barak et al., 2008). On the other hand,
betahistine was shown to limit the excess body weight induced
by the antipsychotic drug olanzapine (Table 1) in a randomized,
double blind placebo controlled pilot study involving 36 patients
with either schizophrenia or schizoaffective disorders (Barak
et al., 2016). In an earlier double blind placebo-controlled study
that involved similar number of enrolled patients, betahistine
potentiated the anorexic effect of the NET blocker reboxetine in
patients receiving olanzapine (Poyurovsky et al., 2013).
Conclusions Regarding Monoamines and Obesity
The study of the mechanism of action of d-fenfluramine led
to completely new drugs which is an interesting achievement.
Additional data are warranted in the field of the control of energy
balance and monoaminergic targets. The reduction of BMI in
obese patients with lorcaserin is estimated in the range of 5–
10%. This is less compared to the actions of previous drugs
amphetamine, d-fenfluramine or sibutramine, but probably
safer. Regarding antipsychotic drugs, newer antipsychotics
(aripiprazole, cariprazine) display a lower affinity at H1 receptor
to prevent weight gain as recommended earlier (Kroeze et al.,
2003). A summary has been indicated in Table 3.
FROM PATHOPHYSIOLOGY TO
TREATMENTS
Parkinson’s Disease
Historical Perspectives
PD is a neurological condition characterized by motor
impairments including bradykinesia, tremor and rigidity
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(Olanow et al., 2009). The symptoms are a consequence of
the degeneration of the nigrostriatal DA tract and appear
approximately when 30% of DA cells in the SNc are destroyed
and/or when striatal tissue DA is reduced by 70% (Burke and
O’Malley, 2013). Comorbid diseases are noticed with prevalence
ranging from 30 to 45% in the case of anxiety or depression
(McDonald et al., 2003). The etiology of the comorbid diseases
is still unknown although other neuronal changes have been
identified including alterations in 5-HT and NA neurons
(Jellinger, 1991; Galati and Di Giovanni, 2010; Delaville et al.,
2011). More generally, PD is a synucleopathy characterized
histopathologically by the presence of Lewy bodies in multiple
brain regions including the SNc and the LC. The lesions of
LC NA neurons occur earlier than SNc DA neurons, and can
reach a higher extent (Del Tredici et al., 2002; Rommelfanger
and Weinshenker, 2007; Delaville et al., 2011). The loss of NA
input to the nigrostriatal DA system could be detrimental for
the function of DA neurons (Benarroch, 2009), conferring
to NA system both a protective role on DA neurons and,
consequently a positive influence regarding the outcome of
treatments. However, available treatments mostly target DA and
not NA-related mechanisms (Table 4).
The treatments of PD depend on the stage of the disease. L-
DOPAwas the first treatment aimed at restoringDA transmission
in the brain. This amino acid can cross the blood brain
barrier (BBB) and reach the striatum before conversion to DA
by AADC. The first trials started in 1961 and L-DOPA still
represents the main pharmacological treatment of PD (Lees
et al., 2015). Years later it was followed by the administration
of DA receptor agonists, and both treatments correspond to
the so-called DA replacement therapy. Deep brain stimulation
of the subthalamic nucleus is a second therapeutic option in
advanced stages of the disease, where patients respond poorly
to medication with motor complications and have no psychiatric
antecedent (Bronstein et al., 2011). A commonly used option at
the onset of the disease, which appears to have few unwanted
side-effects, consists in administration of MAO-B inhibitors such
as L-deprenyl or rasagiline (Rascol et al., 2011; Hauser et al.,
2016).
While the side-effects are still debated in the case of deep brain
stimulation of the subthalamic nucleus (Bronstein et al., 2011),
long-term pharmacological treatments are associated with severe
motor and psychiatric side effects (Bastide et al., 2015).
Mechanisms of Action of Antiparkinsonian Drugs
The therapeutic benefit of L-DOPA and DA receptor agonists has
been related to their indirect and direct actions, respectively, at
DA receptors. L-DOPA has been shown to enhance extracellular
levels of DA in animal models of the disease, using in vivo
methods or in humans indirectly measured by the displacement
of PET ligands binding at DA receptors (de la Fuente-Fernández,
2013; De Deurwaerdère et al., 2016). Since the enzyme AADC
is present in most tissues as well as in brain, much of
the administered L-DOPA was converted at the periphery
to DA, which does not cross the BBB. This problem was
ameliorated by the introduction of benserazide or carbidopa,
two peripheral AADC inhibitors that do not penetrate the brain
(Cotzias, 1968; Cotzias et al., 1969). The introduction of COMT
inhibitors may also increase the efficacy of L-DOPA by limiting
its transformation into 3-O-methyl-DOPA, and, perhaps, by
limiting the inactivation of central DA (Ries et al., 2010). One
of the main side effects of L-DOPA therapy, namely L-DOPA-
induced dyskinesia, has been related to the variation of plasma
L-DOPA concentrations inherent to its oral administration. The
pharmacokinetic challenge is to find a means of smoothing its
plasma concentrations. Similarly, a continuous stimulation of DA
receptors with agonists is an important criterion, and selective
agonists with long-lasting action have been recently synthesized
(Butini et al., 2016).
No real progress has been made regarding the
pharmacodynamics of L-DOPA: researchers attempted either
to boost the ability of L-DOPA to release DA in the striatum
during the 1980’s and the 90’s, or, more recently, to limit the
excess of striatal DA release thereby reducing the occurrence of
dyskinesia. The danger behind these strategies, which focused
on a putative restoration of striatal DA release, magnified by the
implantation of grafts aimed at releasing DA into the caudate-
putamen of patients, is that nobody knows the extent to which
striatal DA release is involved in the benefit and side-effects of
peripheral L-DOPA (De Deurwaerdère et al., 2016). We now
know that L-DOPA-induced dyskinesia and motor benefit can
occur without a measurable enhancement of striatal DA release
in animals (Porras et al., 2014), which confirmed earlier data
raising doubt about the role of striatal DA in the mechanism of
action of L-DOPA (Nakazato and Akiyama, 1989; Fisher et al.,
2000).
In humans, the displacement of raclopride binding was
observed after the intravenous administration of 3 mg/kg L-
DOPA (de la Fuente-Fernández et al., 2004). The authors
reported the displacement of 11C-raclopride binding, but
indicated also that the presumed levels of extracellular DA
produced by the i.v. administration of L-DOPA were lower
in patients compared to healthy individuals (de la Fuente-
Fernández, 2013). A similar situation occurs in rodent models at
comparative, but behaviorally efficacious dosage (Navailles et al.,
2010). The conclusion is that the role of striatal DA release may
have been overestimated in the benefit and possibly in some
side-effects elicited by L-DOPA (De Deurwaerdère et al., 2016).
The overall picture is complicated by the fact that 5-HT
neurons are mainly responsible for the release of DA induced
by L-DOPA in animal models of the disease. The output of DA
is dependent on the integrity of 5-HT neurons (Tanaka et al.,
1999; Navailles et al., 2010). Due to the widespread innervation of
5-HT neurons in the brain, the first consequence is that L-DOPA-
stimulated DA release occurs widely in the brain (Navailles et al.,
2011b; Navailles and De Deurwaerdere, 2012a) (Figure 4), and
this creates a new balance of central DA chemistry (Navailles
and De Deurwaerdère, 2012b). The second consequence is that
striatal DA released by L-DOPA is extremely low for at least
three reasons: (i) the density of striatal 5-HT fibers is 10 to
20 times lower compared to the natural density of DA fibers;
(ii) 5-HT neurons fire around 1 Hz or below and L-DOPA
does not enhance the firing rate of 5-HT neurons (Miguelez
et al., 2016b); DA neurons normally fire above 4 Hz (Bunney
Frontiers in Neuroscience | www.frontiersin.org 12 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
TABLE 4 | Antiparkinsonian drug treatments and pharmacological target.
Pathophysiology Drug in the market Mechanism of action Efficacy at pharmacological target
Degeneration of SNc DA neurons and
striatal DA loss
L-DOPA
DA receptor agonists
In part related to DA increase in the brain,
possibly outside the striatum
Stimulation of D2/3 receptors
Unresolved
Unresolved
Degeneration of LC NA neurons None
Degeneration of neurons—oxidative
stress
MAO-B inhibitors
(Rasagiline)
Unclear Unresolved
The table represents brain alterations in Parkinson’s disease and the drugs and/or strategies used against these alterations. The full spectrum of the mechanism of action of these drugs
may have been misunderstood as no clear efficacy at pharmacological target has been achieved.
et al., 1973; Harden and Grace, 1995); (iii) the intraneuronal
and neurochemical organization of striatal DA neurons (low
metabolism, high rate of translocation into exocytotic vesicles)
is specific to the DA terminals of the striatum and is not
encountered in 5-HT terminals (De Deurwaerdère et al., 2016).
The apparent higher magnitude of response to L-DOPA in the
striatum compared to other brain regions simply corresponds
to the stronger loss of clearance in the striatum due to the loss
of DAT while the clearance of extracellular DA in extrastriatal
regions is in part related to the NET (Navailles et al., 2014)
(Figure 4).
The mechanism of action of L-DOPA is thus unclear and is
likely different from DA agonists. Indeed, the efficacious agonists
in the treatment of PD preferentially target the D2/3 receptors
whereas L-DOPA favors D1 receptor-mediated mechanisms
(Millan, 2010; Butini et al., 2016).
Amelioration of L-DOPA Therapy
There remains scope for improvement in several aspects of L-
DOPA therapy in terms of motor side effects, mood disorders,
psychiatric side-effects and the evolution of the disease.
It has been proposed that excessive swings of extracellular
DA are involved in the dyskinesia induced by L-DOPA (Carta
et al., 2007), although this might not occur in the striatum as
previously claimed. This possibility is supported by the finding
that drugs or conditions that are able to decrease 5-HT neuronal
activity reduced L-DOPA-induced dyskinesia (Bastide et al.,
2015; De Deurwaerdère et al., 2016). Indeed, the mixed 5-
HT1A/1B receptor agonist, 5-HT2C ligand, eltoprazine has been
shown to reduce L-DOPA-induced dyskinesia in humans and
animal models of the disease (Bezard et al., 2013; Svenningsson
et al., 2015; Tronci et al., 2015). The efficacy of eltoprazine is not
superior to existing treatment such as amantadine (Bezard and
Carta, 2015). In terms of new strategies, particular attention has
been given to 5-HT1A receptor biased agonists, such as NLX-
112, which acts preferentially at somatodendritic, rather than
post-synaptic, 5-HT1A receptors (Iderberg et al., 2015; McCreary
et al., 2016). It has also been proposed that SSRIs lower L-
DOPA-induced dyskinesia, as a result of their ability to indirectly
reduce the firing rate of 5-HT neurons in the DRN (see above
for the mechanism of action). The efficacy of SSRIs against L-
DOPA-induced dyskinesia in humans is modest (Durif et al.,
1995; Mazzucchi et al., 2015), and this is also found in animal
models of PD (Fidalgo et al., 2015; Miguelez et al., 2016a).
Indeed, higher doses of SSRIs are required, compared to those
effective in normal individuals. This may be due to the action
of L-DOPA inside the 5-HT neurons, impairing their normal
biochemical processes and altering 5-HT release (Miguelez et al.,
2016b), thereby dampening the reactivity of 5-HT neurons to
SSRIs administration (Miguelez et al., 2016a). Other strategies
that have been tested include D3 receptor antagonists or partial
agonists (Bézard et al., 2003; Visanji et al., 2009). In addition to
L-DOPA-induced dyskinesia, the D3 receptor subtype remains
an important target in the treatment of PD with D2/3 receptor
agonists (pramipexol, piribedil, ropinirole) (Millan, 2010; Leggio
et al., 2016; Perez-Lloret and Rascol, 2016) being assessed in
the management of impulsive-control disorder consequent to
L-DOPA/DA receptor agonist administration (Seeman, 2015).
Noradrenergic compounds have also been proposed to limit the
occurrence of dyskinesia but the data are unclear (Delaville et al.,
2011; Fox, 2013; Bhide et al., 2015; De Deurwaerdère et al., 2016).
The mechanism of action of L-DOPA toward 5-HT neurons
also informs the therapeutic strategies for the mood disorders
in PD, whose prevalence is higher compared to depressed
individuals without PD (McDonald et al., 2003). Nowadays, the
use of SSRIs remains a first line treatment in PD but, due to
the specific action of L-DOPA on 5-HT neuron activity, the
use of SSRIs might not be the best approach (Liu et al., 2013;
De Deurwaerdère and Ding, 2016). Other strategies, based on
the blockade of post-synaptic 5-HT or NA receptors, MAO-Is,
SNRIs or DA receptor agonists, are available. An entire field of
research has to be devoted to addressing this question, and also
considering that the etiology of mood disorders in Parkinson’s
disease could be different from classical depression.
The psychotic side effects of DA agonists and L-DOPA have
a high prevalence in advanced stage of the disease (Melamed
et al., 1996). Historically, these effects have been associated
with an excessive DA tone produced by L-DOPA or DA
agonists. Interestingly, the 5-HT2A receptor inverse agonist
primavanserin has been shown to be effective in reducing L-
DOPA-induced psychosis (Meltzer et al., 2010; Markham, 2016).
It might replace the use of atypical antipsychotics quetiapine or
clozapine (Friedman and Factor, 2000; Chang and Fox, 2016).
The mechanisms behind the efficacy of primavanserin are, as yet,
unclear.
Finally, MAO-B inhibitors L-deprenyl, safinamide,
zonisamide or rasagiline have been shown to be efficacious
in the treatment of PD either as unique treatment in the early
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FIGURE 4 | Mechanisms of action of L-DOPA on brain DA release. The upper illustration recalls the origin of ascending fibers for monoamines. The lower
displays the normal dopaminergic transmission in the striatum (very dense) and the prefrontal cortex (very low). It includes serotonergic and noradrenergic terminals
with their relative density compared to DA terminals. In the 6-hydroxydopamine rat model of PD, the density of dopaminergic fibers drop to less than 10% of the
normal situation and the increase in DA release induced by L-DOPA is mostly due to serotonergic terminals. DA reuptake by noradrenergic fibers is low in the striatum
due to their poor density. The overall output of striatal DA induced by L-DOPA, identified in the figure by the blue background, is very low compared to the
physiological situation without L-DOPA. In the prefrontal cortex, the overall output of DA induced by L-DOPA is higher compared to the physiological situation because
the density of serotonergic terminals is higher than the natural density of dopaminergic terminals. The reuptake of DA by NA fibers is magnified in L-DOPA-treated
animals. The situation described in the prefrontal cortex is also observed in the hippocampus or the substantia nigra pars reticulata (not shown here) and virtually in
most brain regions (De Deurwaerdère and Di Giovanni, 2016; De Deurwaerdère et al., 2016).
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stages of the disease or in conjunction with L-DOPA (Youdim
et al., 2006; Riederer and Laux, 2011; Fox, 2013; Finberg, 2014).
Since MAO-B is not primarily involved in the presynaptic
inactivation of DA, it is possible that these compounds act at the
glial level during L-DOPA therapy. In this context, L-DOPA has
been shown to destroy 5-HT neurons upon chronic exposure in
rodents (Navailles et al., 2011a; Stansley and Yamamoto, 2013,
2014), an effect related to an increase in metabolic stress which
is blocked by antioxidant drugs including MAO-B inhibitors
(Stansley and Yamamoto, 2014). The reduction of oxidative stress
by MAO-B inhibitors might also reduce the destruction of DA
neurons. MAO-B inhibitors of this type have also been shown
to have antiapoptotic actions in a number of model systems (see
(Youdim et al., 2006). Thus, the effects of these compounds in
PD may be multifactorial.
Conclusion
The mechanisms behind the DA replacement therapy are
unclear, because the mechanism of action of L-DOPA is still
not understood in terms of its neurochemical effects, which
differ from those of DA receptor agonists or MAO-B inhibitors
(Table 4 for a summary). Therefore, the antiparkinsonian agents
do not work as it was initially thought and this could explain
why no major progress in terms of pharmacodynamics has been
made. In the case of L-DOPA, it will be necessary to determine
the roles of DA and the brain location of its effects, in order to
regionally control DA tone from 5-HT neurons (Navailles and
De Deurwaerdère, 2012b; Navailles et al., 2015).
Several models using transgene animals or injection of viral
constructs targeting proteins involved in the familial forms
of the disease have been raised during recent years (Bezard
and Przedborski, 2011). Although these models are still under
pathophysiological examination, they might open new ways of
treatments, even beyond monoamines.
Drug Addiction
Historical Perspective
The addictive properties of numerous drugs including alcohol
and tobacco, the opiates (opium, morphine, heroin) and
the psychostimulant drugs amphetamine and cocaine, were
recognized before the existence and significance of the DA
reward system in the brain was known. Studies of drug addiction
received an increased impetus when the primary physiological
target in the brain was thought to be determined, namely the
DA neurons from the VTA innervating the nucleus accumbens.
All drugs of abuse share similar neurobiological property, since
they increase DA release in the nucleus accumbens that parallels
the reinforcing properties of the drugs (Di Chiara and Imperato,
1988; Di Chiara, 1992; Koob, 1992). While the action of drug
of abuse on DA neurons can be viewed as an initiating step,
the addiction is a much more complex behavioral disturbance. It
involves alterations of neurobiological and humoral mechanisms
in sequential steps (LeMoal and Simon, 1991; Koob and LeMoal,
1997, 2008; Koob et al., 2014), and is marked by inter-individual
differences, spreading drug addiction as a disease (Deroche-
Gamonet et al., 2004; Ahmed, 2010). In spite of the numerous
studies focusing on the activity of DA neurons as a possibility to
avoid relapse and to reduce drug intake, it is possible that DA
transmission is no longer an appropriate target once addiction
is established. At present, no DA drug is given to drug addicts
although some substituted drugs targeting theDAT are developed
(Hiranita et al., 2014) by analogy with methadone for opiates
abuse.
Mechanism of Action
The mechanisms of action of drugs of abuse toward DA
neuronal activity differ according to the drug of abuse, and
most of them, classically, enhance DA outflow through an
increase in impulse flow, whereas psychostimulants promote
DA outflow independently from DA neuronal impulse. Gaetano
Di Chiara’s team has first demonstrated that this distinction
was probably fundamental, in view of the control of DA
neuronal activity and subsequent behavioral outcomes that
can be expected from various targets, particularly 5-HT3
receptors (Carboni et al., 1989). 5-HT3 receptor antagonists
counteracted place preference and the enhancement of DA
release induced by drugs enhancing DA neuron firing rate.
After that discovery (see De Deurwaerdère and Di Giovanni,
2016), 5-HT2A receptor antagonists were shown to counteract
the non-exocytotic release of DA induced by amphetamine
or 3,4-Methylenedioxymethamphetamine (ecstasy), whereas 5-
HT2C receptor agonists inhibited the impulse-dependent release
of DA. In parallel, behavioral data have shown that 5-HT2C
receptor agonists and 5-HT2A receptor antagonists were capable
of dampening the reinforcing properties, the craving and
relapse, produced by drugs of abuse, in particular cocaine
(Fletcher and Higgins, 2011; Higgins and Fletcher, 2015; Howell
and Cunningham, 2015). However, the involvement of DA
mechanisms in the benefit of these 5-HT compounds is far from
clear, suggesting that the measurement of DA neuronal activity
or release is not the most appropriate neurobiological marker
of the anti-addictive behavior of therapeutic approaches (De
Deurwaerdère and Di Giovanni, 2016).
Other monoaminergic approaches gave promising preclinical
results, especially D3 receptor antagonists (Leggio et al., 2016).
A better determination of the involvement of other systems in
addiction might lead to complete new treatment strategies.
DISEASES WITHOUT CURRENT
MONOAMINERGIC TREATMENTS
Epilepsy
Epilepsy is characterized by seizures whose magnitude varies
from almost undetectable to intense shaking. Sudden and
unprovoked synchrony of bursts of neuronal hyperactivity can
be “focal” if it remains confined to the area of origin, or
“generalized.” The origin of this condition is unknown even
though genetic predisposition factors have been identified in
some cases. Although it manifests as abnormal neuronal activity,
it is possible that glial cells play a substantial role in triggering or
maintaining this abnormality (Devinsky et al., 2013). Abnormal
astrocytic function has been found in models of epilepsy,
including the inability to maintain an appropriate extracellular
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milieu through different mechanisms (Coulter and Steinhäuser,
2015).
Monoaminergic drugs are not in the armamentarium of anti-
epileptic drugs, although they have been the object of numerous
articles. The monoamine enhancing antidepressant drugs were
contraindicated in patients with epilepsy (Jobe and Browning,
2005). Nevertheless, antidepressants such as SNRIs or SSRIs
were commonly prescribed to patients to reduce symptoms of
comorbid depression and/or anxiety (Cardamone et al., 2013).
Against the initial assumption, preclinical and human studies
tend to indicate that SSRIs or SNRIs have an anticonvulsant
profile, which can improve seizure outcomes (Cardamone et al.,
2013). Moreover, SNRIs and SSRIs could limit the occurrence of
seizures in depressed patients rather than increase them (Alper
et al., 2007). Additional studies are warranted to evaluate the
benefit of monoamine-based antidepressant drugs in clinical
praxis (see Strac et al., 2016).
SSRIs and SNRIs, as discussed above, can promote numerous
mechanisms other than a simple increase in extracellular
monoamine levels (Dale et al., 2015). Indeed, one “pseudo-
monoaminergic treatment,” namely zonisamide, has received
approval for the treatment of epilepsy (Bialer, 2012). Zonisamide
interacts with human MAO-B, but not MAO-A (Binda
et al., 2011). Similarly, L-deprenyl, the prototypical irreversible
MAO-B inhibitor (Ramsay, 2013), has anticonvulsant and
antiepileptogenic properties. The mechanisms triggered by these
drugs are complex and likely not only related to MAO-B
inhibition (Strac et al., 2016).
The roles of individual monoamines and their receptors have
been the subject of many studies. To date, no specific target or a
combination of specific targets has been approved for epilepsy.
In the accompanying paper (Strac et al., 2016), we consider
the potential interest of agonistic activity at 5-HT2C/D2/α2-
adrenergic receptors and antagonistic activity at H3 receptors.
It is intriguing that, after years of research, the favorable targets
indicated from preclinical studies are those involved in tonic
control of neurobiological networks and neuronal activity in the
mammalian brain.
Alzheimer’s Disease
The oldest of the various hypotheses, proposed in order to
explain AD pathogenesis involves the cholinergic system (Sims
et al., 1980). Others include the most comprehensive amyloid-β
cascade (Karran et al., 2011), glutamate/calcium neurotoxicity
(Karran et al., 2011), and hyperphosphorylated tau protein
(Li et al., 2007). Recent studies have revealed an association
of oxidative imbalance and stress with neuron degeneration
(Guidi et al., 2006), and implicated nitric oxide and other
reactive nitrogen species (McCann et al., 2005). Accordingly, in
addition to the four clinically approved compounds (donepezil,
rivastigmine, galantamine, and memantine), that target
cholinergic and glutamatergic systems (Parsons et al., 2013), new
approaches, focused on the prevention or decline of amyloid
cascade events, formation of tangles, oxidative injury, and
inflammation, have been proposed for the AD treatment (Ittner
and Götz, 2011). It has been suggested that AD patients might
benefit from multi-target medication, such as treatment with
acetylcholinesterase inhibitors (AChEIs) in combination with
memantine (Lopez et al., 2009).
As neuronal degeneration in AD also affects monoaminergic
systems (Trillo et al., 2013), dopaminergic and serotonergic
dysfunction has been also proposed to be involved (Martorana
and Koch, 2014; Claeysen et al., 2015; Šimic´ et al., 2016),
suggesting additional therapeutic targets for AD. Newly
synthetized molecules with neuroprotective and multimodal
mechanisms of action, currently in different phases of preclinical
or clinical investigations (Dias and Viegas, 2014), act not only
as AChEI and modulators of Aβ-aggregation (Tonelli et al.,
2015), but also at voltage-dependent calcium channels (León
and Marco-Contelles, 2011), MAO activity (Bautista-Aguilera
et al., 2014), 5-HT3 receptors (Fakhfouri et al., 2012) and
N-methyl-D-aspartate (NMDA) receptors (Simoni et al., 2012).
Reduced DA levels in the brain (Storga et al., 1996),
cerebrospinal fluid (CSF) (Tohgi et al., 1992) and urine (Liu et al.,
2011), as well as lower brain levels of L-DOPA and DOPAC have
been found in AD patients (Storga et al., 1996). Individuals with
AD also exhibit reduced expression of DA receptors (Kumar
and Patel, 2007), DAT, and TH (Joyce et al., 1997) in different
brain regions. The COMT Val158Met polymorphism, which
affects the COMT activity, has been associated with the risk of
AD (Yan et al., 2016). The role of dopaminergic system in AD
was confirmed by findings showing that L-DOPA (Martorana
et al., 2009), the MAO-B inhibitor l-deprenyl (Filip and Kolibás,
1999), and the D2 agonist rotigotine (Koch et al., 2014), have
beneficial effects on cognitive functions in AD patients. The Aβ
accumulation seems to be involved in dopaminergic dysfunction,
contributing to the extrapyramidal deficits and rapid cognitive
decline in AD patients (Preda et al., 2008). Inhibitors of
COMT, like tolcapone, reduce Aβ aggregation by stabilizing
its monomeric state (Di Giovanni et al., 2010), while the DA
receptor agonist apomorphine promotes Aβ degradation and
improves memory (Himeno et al., 2011). While most treatments
in clinical trials tend to increase DA function, the antipsychotic
drugs haloperidol and risperidone have reached the phase IV of
clinical trials (Šimic´ et al., 2016).
Degeneration of NA neurons, observed in the early stages
of AD, in mild cognitive impairment, and even in younger
individuals with still normal cognitive function, indicates that
alterations in noradrenergic systemmight precede Aβ deposition
(Arai et al., 1992; Grudzien et al., 2007; Braak and Del Tredici,
2011). Lower levels of NA in CSF (Liu et al., 1991), TH in
the brain, and DBH in the brain and plasma (Iversen et al.,
1983; Mustapic et al., 2013) as well as decreased binding of
α2 adrenergic receptors (which inhibit the release of NA) in
the brain are found in AD patients (Kalaria and Andorn,
1991; Pascual et al., 1992). However, some studies proposed
compensatory mechanisms in AD resulting in increased levels of
NA (Elrod et al., 1997; Peskind et al., 2005) and TH (Szot et al.,
2006).
NA pharmacotherapy has been used primarily to treat
different behavioral and psychological symptoms of dementia
(BPSD). Propranolol was proposed for the treatment of
aggression or agitation (Greendyke et al., 1986; Shankle et al.,
1995), and imipramine for treatment of depression in AD
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(Reifler et al., 1989). However, NA-enhancing therapy could
be also used to treat cognitive impairments in patients with
dementia. Combination of the NA prodrug L-DOPS and
the NET inhibitor atomoxetine was shown to elevate NA
levels, increase expression of brain-derived neurotrophic
factor and different enzymes involved in Aβ degradation,
resulting in improved spatial memory (Kalinin et al.,
2012). Reboxetine is currently tested in clinic (Šimic´ et al.,
2016).
Studies suggest that NA deficiency induces inflammatory
response by elevating Aβ deposition and reducing microglial Aβ
phagocytosis (Heneka et al., 2002, 2010), thus contributing to
AD progression. Moreover, it appears that low DBH activity,
associated with -1021C/T DBH regulatory polymorphism,
increases the risk for AD in combination with interleukin 1
alpha polymorphisms (Mateo et al., 2006; Combarros et al.,
2010). These findings suggest the potential of NA to slow down
the neurodegeneration process by stimulating anti-inflammatory
responses, microglial migration and phagocytosis, thereby
contributing to Aβ clearance. Future studies should evaluate
proposed anti-inflammatory and neuroprotective mechanisms of
NA pharmacotherapy as therapeutic strategy in AD patients.
Lower number/activity of 5-HT neurons (Aletrino et al., 1992;
Meltzer et al., 1998), as well as decreased concentration of 5-
HT and its metabolites in the brain (Garcia-Alloza et al., 2005),
CSF (Tohgi et al., 1992) and blood platelets (Muck-Seler et al.,
2009) suggested a role of the serotonergic system in AD (Terry
et al., 2008; Ramirez et al., 2014). A progressive decline in the
density of different brain 5-HT receptors was observed in AD
patients (Reynolds et al., 1995; Lai et al., 2003; Garcia-Alloza et al.,
2004; Kepe et al., 2006; Lorke et al., 2006; Marner et al., 2012),
sometimes correlating with the severity of cognitive impairment
(Versijpt et al., 2003; Lai et al., 2005). Such changes in the
serotonergic system could be also associated with BPSD (Lanari
et al., 2006).
The association of 5-HT signaling with accumulation of
Aβ plaques (Holm et al., 2010; Cirrito et al., 2011), and
improvement in cognitive performance after treatment with
5-HT modulators (Payton et al., 2003; Geldenhuys and Van
der Schyf, 2011; Ramirez et al., 2014), point to serotonergic
system as a potential target for AD therapy. Both in vivo and
in vitro studies demonstrated the potential of different agonists
and/or antagonists of various 5-HT receptors for treating AD,
including those affecting 5-HT1A, 5-HT4, and 5-HT6 receptors
(Meneses, 2013; Ramirez et al., 2014; Šimic´ et al., 2016;
Werner and Covenas, 2016). The development of serotonergic
medications which interact with multiple targets (Rezvani et al.,
2009; Fakhfouri et al., 2015; Leiser et al., 2015; Stahl, 2015),
could be a promising approach for AD treatment. The most
advanced clinical trials focus on the 5-HT1A receptor agonists,
tandospirone or buspirone, as well as citalopram (Šimic´ et al.,
2016).
Multitarget drug design is also used, targeting enzymes
involved in oxidative stress and inflammation, and these
strategies are likely to interfere with monoamine tone. This
research is presented in the next section.
Ischemic Stroke/Oxidative Stress
Stroke is a vascular disorder that constitutes the second leading
cause of death worldwide with higher incidence in elderly
people. Inflammation and oxidative stress, accumulated during
human aging, negatively influence the vascular damage following
a stroke incident (DiNapoli et al., 2008), and the immune
system may contribute to the infarct progression (Iadecola and
Anrather, 2011). Human brain is highly demanding of oxygen.
It accounts for the 20% of the body oxygen consumption. This
high demand of energy makes the brain highly dependent on
cerebral blood supply and an organ especially susceptible to
the deleterious effect of hypoxia. Two different types of stroke
occur. Ischemic stroke that occurs in the blood vessels of the
brain as a consequence of the formed clots, preventing oxygen
arrival to the brain cells and inducing a hypoxic condition.
About 80% of all strokes are ischemic. On the other hand, the
hemorrhagic stroke occurs when a blood vessel in the brain
breaks or ruptures as a consequence of high blood pressure
or brain aneurysms, resulting in the blood seeping into the
cerebral tissue, causing damage to the brain cells. Actually, the
fact that a high percentage of patients having suffered stroke
subsequently developed AD, indicates a strong link between
these two pathologies. In this context, hypoxia and ischemic
injury induce the up-regulation of beta secretase 1 (BACE-1) that
increases the β-amyloid formation (Guglielmotto et al., 2009).
Increasing evidence suggest that the neurovasculature plays an
important role in the onset and progression of neurological
disorders like AD (Zlokovic, 2008; Grammas, 2011; Marchesi,
2014). This has led to the concept of “neurovascular unit,”
integrated by neurons, astrocytes and vascular cells, which
constitutes a functional unit able to maintain the homeostasis of
the brain’s microenvironment (Iadecola, 2010). Different amine
oxidases are present in this “neurovascular unit” and they could
play an important role under physiological and pathological
conditions.
As discussed above, MAOs are involved in the metabolism
of biogenic amines. MAO-Is provide additional benefits in
neurologic disorders by reducing the formation of neurotoxic
products such as hydrogen peroxide and aldehydes, which are
derived from MAO activities. In neurodegeneration, MAO-I,
especially those containing a propargylamine group, have been
reported to possess multiple beneficial activities including
neuroprotective, anti-apoptotic and antioxidant properties
(Jenner, 2004; Sanz et al., 2004, 2008; Bar-Am et al., 2005).
Another amine oxidase present in cerebrovascular tissue,
mainly in endothelial cells constituting the BBB, also plays
a role in neurological disorders. Vascular adhesion protein 1
(VAP-1) is a homodimer glycoprotein with enzymatic function
that binds leukocytes through its semicarbazide sensitive amine
oxidase (SSAO) activity inducing inflammation (Smith et al.,
1998; Jalkanen and Salmi, 2008). SSAO/VAP-1 metabolizes
only primary amines producing aldehydes, hydrogen peroxide
and ammonia, which are able to induce oxidative stress and
cellular damage when overproduced (Yu and Deng, 1998).
SSAO/VAP-1 is localized at the cell membrane and is released
into blood as soluble form that is altered in several human
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pathologies (Kurkijärvi et al., 1998; Boomsma et al., 2003),
including AD (Ferrer et al., 2002; del Mar Hernandez et al.,
2005) and cerebral ischemia (Airas et al., 2008). The mediators
that induce these alterations in the SSAO/VAP-1 levels are
still unknown, but it is believed that increased SSAO/VAP-1
levels may contribute to the physiopathology of these diseases,
thus constituting a potential therapeutic target (Conklin et al.,
1998; Solé et al., 2008). Actually, human plasma SSAO activity
is a strong predictor of parenchymal hemorrhages after tissue
plasminogen activator (tPA) treatment in ischemic stroke
patients (Hernandez-Guillamon et al., 2010), and plasma SSAO
activity, which is also elevated in hemorrhagic stroke patients,
predicts their neurological outcome (Hernandez-Guillamon
et al., 2012). Considering all these data, SSAO/VAP-1 could
mediate the link between stroke and the progression to AD
through the alteration of the cerebrovascular function.
In spite of the different cellular localization of both MAO
isoforms as well as SSAO/VAP-1, and their different substrate
specificities, a cross-talk between these oxidases occurs. It
has been described that MAO modulates the behavior of
SSAO/VAP-1 (Fitzgerald and Tipton, 2002) and SSAO/VAP-1
may compensate in some extent the deficit in the oxidative
deaminating capacity in situations where MAO activity is
dysfunctional (Murphy et al., 1991).
Dynamic communication between cells of the neurovascular
unit is required for normal brain functioning. The neurovascular
unit consists of all major cellular components of the brain
including neurons, astrocytes, brain endothelium, pericytes,
vascular smooth muscle cells, microglia, and perivascular
macrophages. In a situation of hemorrhagic stroke, an alteration
of the homeostasis between all components of the neurovascular
unit occurs, and the role of amine oxidases, especially the
SSAO/VAP-1 activity is increased, contributing through its
catalytic activity to the oxidative stress and inflammation
(Hernandez-Guillamon et al., 2012). The neurovascular
unit disruption may also alter the neuronal monoaminergic
transmission. In this context, a pharmacological approach that
is able to interact simultaneously with different amine oxidases
might be a novel and more effective therapeutic approach
(Solé et al., 2015; Sun et al., 2015). The close relationship
between AD and stroke and the involvement of SSAO/VAP-1
in both diseases suggests that the synthesis and design of the
new multitarget drugs, able to interact with different types of
amine oxidases (MAO-A, MAO-B, and SSAO/VAP-1), could
provide a useful therapeutic approach that is able to modulate
the monoaminergic transmission, to protect the BBB, and
hence avoid the progression of both neurological disorders.
It should be noted that oxidative stress is recurring feature of
several theories of the etiology of neurodegenerative diseases,
which might be addressed by reducing hydrogen peroxide
formation.
Concluding Remarks
Despite the progress made on the influence of monoamines
in the three above-mentioned diseases, no monoamine-based
treatments are available at present. In most cases, one emerging
strategy would be the use of SSRI or MAO-Is, two approaches
that are altering monoaminergic transmission throughout the
brain rather than a specific monoaminergic drug targeting
the injured tissue. In fact, there are two interconnecting
issues: one addressing the regional origin of the disease,
and the other addressing the functional consequences away
from the dysfunctional site. Assuming that the benefit of
antidepressant drugs like SSRI orMAO-I is related to the ultimate
reorganization of neurobiological networks, their possible benefit
could be related to actions away from the injured sites.
GENERAL CONCLUDING REMARKS
Monoaminergic drugs affect different processes in the brain
that control the tone of neurotransmission or/and tissue
excitability, and therefore should be studied as future targets
for novel therapeutic approaches, not only for depression,
but also for schizophrenia, addiction, obesity, PD, epilepsy,
AD and stroke. This analysis acknowledges the Neuroscience
based Nomenclature proposed by the IUPHAR which is based
on the pharmacological profiles of psychotropic drugs rather
than the clinical indication (Zohar et al., 2015). Common
approaches involve the use of agents acting on monoaminergic
transporters, D2, D3, 5-HT2B/2C, 5-HT1A, 5-HT2A, H3, or
α2 receptors. All these targets, apart the 5-HT2A receptor,
exert widespread influences in the brain and alter multiple
brain functions simultaneously. Thus, compounds affecting
monoaminergic transmission have numerous consequences for
the brain and its neurobiological networks. While researchers
are aware that the symptomatic treatment of a disease results
frommultiple actions on the brain function, the linkages enabling
a favorable reorganization of brain function after monoamine-
based treatments are still not fully understood.
The search for effective targets in the treatment of brain
diseases was facilitated by the serendipitous discoveries of
compounds that were efficacious in schizophrenia, depression
and obesity. Several new compounds have been developed
that retain the original pharmacological targets involved in
those therapeutic benefits combined with actions on new
targets, identified from subsequent research, whilst aiming to
minimize undesirable “off-target” actions. Knowledge of the
monoaminergic mechanisms underlying drug efficacy led to
the development of drugs with more specific mechanisms
of action; lorcaserin, agomelatine, and vortioxetine are
interesting achievements in this context. The identification
of pathophysiological causes to tailor appropriate therapeutic
approaches has been less successful. It has shown some success
with PD but not with addiction to drug of abuse. Nonetheless,
the failure to improve on current antiparkinsonian therapies
confirms that the efficacy of these treatments is not simply related
to a compensation of the loss of striatal DA. To some extent, the
remarkable clinical success of L-DOPA was serendipitous. It is
difficult to implement new monoaminergic treatment strategies
in the clinic unless they depend on those currently accepted. This
is exemplified by the third group of diseases where the progress
regarding the involvement of monoamines in these diseases has
not yet resulted in new monoamine-based treatments.
Current attempts to address the full spectrum of action
of existing drugs can be improved. It is to be hoped
that novel approaches, such as connectomics with polyomic
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research addressing brain functions, neurobiological networks,
monoaminergic systems and their mutual interactions, might
offer new perspectives and enhance the current state-of-the-
art biological research in these psychiatric and neurological
disorders.
AUTHOR CONTRIBUTIONS
All authors contributed to the conception and interpretation
of the work and to its critical revision. All authors
have approved the final version and may be held
accountable for the integrity of this review of current
literature.
ACKNOWLEDGMENTS
Support was kindly provided by the EU COST Action CM1103.
GD kindly acknowledgesMCSTR&I 2013-014. PD acknowledges
the “Fondation de France” and the Centre National de la
Recherche Scientifique.”
REFERENCES
Adell, A., Carceller, A., and Artigas, F. (1993). In vivo brain dialysis study of the
somatodendritic release of serotonin in the Raphe nuclei of the rat: effects of 8-
hydroxy-2-(di-n-propylamino)tetralin. J. Neurochem. 60, 1673–1681. doi: 10.
1111/j.1471-4159.1993.tb13390.x
Ahles, A., and Engelhardt, S. (2014). Polymorphic variants of adrenoceptors:
pharmacology, physiology, and role in disease. Pharmacol. Rev. 66, 598–637.
doi: 10.1124/pr.113.008219
Ahmed, S. H. (2010). Validation crisis in animal models of drug addiction: beyond
non-disordered drug use toward drug addiction. Neurosci. Biobehav. Rev. 35,
172–184. doi: 10.1016/j.neubiorev.2010.04.005
Airas, L., Lindsberg, P. J., Karjalainen-Lindsberg, M. L., Mononen, I., Kotisaari,
K., Smith, D. J., et al. (2008). Vascular adhesion protein-1 in human ischaemic
stroke. Neuropathol. Appl. Neurobiol. 34, 394–402. doi: 10.1111/j.1365-2990.
2007.00911.x
Aletrino,M. A., Vogels, O. J., VanDomburg, P. H., and TenDonkelaar, H. J. (1992).
Cell loss in the nucleus raphes dorsalis in Alzheimer’s disease. Neurobiol. Aging
13, 461–468. doi: 10.1016/0197-4580(92)90073-7
Alper, K., Schwartz, K. A., Kolts, R. L., and Khan, A. (2007). Seizure incidence
in psychopharmacological clinical trials: an analysis of Food and Drug
Administration (FDA) summary basis of approval reports. Biol. Psychiatry 62,
345–354. doi: 10.1016/j.biopsych.2006.09.023
Andersson, K. E. (1980). Adrenoceptors–classification, activation and blockade by
drugs. Postgrad. Med. J. 56(Suppl. 2), 7–16.
Arai, H., Ichimiya, Y., Kosaka, K., Moroji, T., and Iizuka, R. (1992).
Neurotransmitter changes in early- and late-onset Alzheimer-type dementia.
Prog. Neuropsychopharmacol. Biol. Psychiatry 16, 883–890. doi: 10.1016/0278-
5846(92)90106-O
Arrang, J. M., Garbarg, M., Quach, T. T., Dam Trung Tuong, M., Yeramian,
E., and Schwartz, J. C. (1985). Actions of betahistine at histamine receptors
in the brain. Eur. J. Pharmacol. 111, 73–84. doi: 10.1016/0014-2999(85)
90115-3
Artigas, F. (2013). Serotonin receptors involved in antidepressant effects.
Pharmacol. Ther. 137, 119–131. doi: 10.1016/j.pharmthera.2012.09.006
Artigas, F. (2015). Developments in the field of antidepressants, where do we go
now? Eur. Neuropsychopharmacol. 25, 657–670. doi: 10.1016/j.euroneuro.2013.
04.013
Artigas, F., Nutt, D. J., and Shelton, R. (2002). Mechanism of action of
antidepressants. Psychopharmacol. Bull. 36(Suppl. 2), 123–132.
Artigas, F., Romero, L., de Montigny, C., and Blier, P. (1996). Acceleration
of the effect of selected antidepressant drugs in major depression by 5-
HT1A antagonists. Trends Neurosci. 19, 378–383. doi: 10.1016/S0166-2236(96)
10037-0
Ashby, C. R. Jr., and Wang, R. Y. (1996). Pharmacological actions of the atypical
antipsychotic drug clozapine: a review. Synapse 24, 349–394.
Ban, T. A. (2001). Pharmacotherapy of depression: a historical analysis. J. Neural
Transm. (Vienna) 108, 707–716. doi: 10.1007/s007020170047
Barak, N., Beck, Y., and Albeck, J. H. (2016). A randomized, double-blind,
placebo-controlled pilot study of betahistine to counteract olanzapine-
associated weight gain. J. Clin. Psychopharmacol. 36, 253–256. doi: 10.1097/JCP.
0000000000000489
Barak, N., Greenway, F. L., Fujioka, K., Aronne, L. J., and Kushner, R. F. (2008).
Effect of histaminergic manipulation on weight in obese adults: a randomized
placebo controlled trial. Int. J. Obes. (Lond). 32, 1559–1565. doi: 10.1038/ijo.
2008.135
Bar-Am, O., Weinreb, O., Amit, T., and Youdim, M. B. (2005). Regulation of Bcl-2
family proteins, neurotrophic factors, and APP processing in the neurorescue
activity of propargylamine. FASEB J. 19, 1899–1901. doi: 10.1096/fj.05-3794fje
Barnes, N. M., and Sharp, T. (1999). A review of central 5-HT receptors
and their function. Neuropharmacology 38, 1083–1152. doi: 10.1016/S0028-
3908(99)00010-6
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P. O., Feyder,
M., et al. (2015). Pathophysiology of L-dopa-induced motor and non-motor
complications in Parkinson’s disease. Prog. Neurobiol. 132, 96–168. doi: 10.
1016/j.pneurobio.2015.07.002
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., and
Brecher, M. (2009). Extended-release quetiapine as adjunct to an antidepressant
in patients with major depressive disorder: results of a randomized, placebo-
controlled, double-blind study. J. Clin. Psychiatry 70, 540–549. doi: 10.4088/
JCP.08m04629
Bautista-Aguilera, O. M., Esteban, G., Chioua, M., Nikolic, K., Agbaba, D.,
Moraleda, I., et al. (2014). Multipotent cholinesterase/monoamine oxidase
inhibitors for the treatment of Alzheimer’s disease: design, synthesis,
biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of
novel donepezil-pyridyl hybrids. Drug Des. Devel. Ther. 8, 1893–1910. doi: 10.
2147/DDDT.S69258
Beaulieu, J. M., and Gainetdinov, R. R. (2011). The physiology, signaling, and
pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217. doi: 10.
1124/pr.110.002642
Bel, N., and Artigas, F. (1992). Fluvoxamine preferentially increases extracellular
5-hydroxytryptamine in the raphe nuclei: an in vivomicrodialysis study. Eur. J.
Pharmacol. 229, 101–103. doi: 10.1016/0014-2999(92)90292-C
Benarroch, E. E. (2009). The locus ceruleus norepinephrine system: functional
organization and potential clinical significance. Neurology 73, 1699–1704.
doi: 10.1212/WNL.0b013e3181c2937c
Berman, R.M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson,W. H., Corey-
Lisle, P. K., et al. (2007). The efficacy and safety of aripiprazole as adjunctive
therapy in major depressive disorder: a multicenter, randomized, double-blind,
placebo-controlled study. J. Clin. Psychiatry 68, 843–853. doi: 10.4088/JCP.
v68n0604
Bett, W. R. (1946). Benzedrine sulphate in clinical medicine; a survey of the
literature. Postgrad. Med. J. 22, 205–218. doi: 10.1136/pgmj.22.250.205
Bezard, E., and Carta, M. (2015). Could the serotonin theory give rise to
a treatment for levodopa-induced dyskinesia in Parkinson’s disease? Brain
138(Pt 4), 829–830. doi: 10.1093/brain/awu407
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., et al. (2003).
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3
receptor function. Nat. Med. 9, 762–767. doi: 10.1038/nm875
Bezard, E., and Przedborski, S. (2011). A tale on animal models of Parkinson’s
disease.Mov. Disord. 26, 993–1002. doi: 10.1002/mds.23696
Bezard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., et al. (2013).
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-
induced dyskinesia.Mov. Disord. 28, 1088–1096. doi: 10.1002/mds.25366
Bhide, N., Lindenbach, D., Barnum, C. J., George, J. A., Surrena, M. A., and Bishop,
C. (2015). Effects of the beta-adrenergic receptor antagonist Propranolol on
dyskinesia and L-DOPA-induced striatal DA eﬄux in the hemi-parkinsonian
rat. J. Neurochem. 134, 222–232. doi: 10.1111/jnc.13125
Frontiers in Neuroscience | www.frontiersin.org 19 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Bialer, M. (2012). Chemical properties of antiepileptic drugs (AEDs). Adv. Drug
Deliv. Rev. 64, 887–895. doi: 10.1016/j.addr.2011.11.006
Binda, C., Aldeco, M., Mattevi, A., and Edmondson, D. E. (2011). Interactions
of monoamine oxidases with the antiepileptic drug zonisamide: specificity of
inhibition and structure of the human monoamine oxidase B complex. J. Med.
Chem. 54, 909–912. doi: 10.1021/jm101359c
Blier, P., and de Montigny, C. (1990). Electrophysiological investigation of the
adaptive response of the 5-HT system to the administration of 5-HT1A
receptor agonists. J. Cardiovasc. Pharmacol. 15(Suppl. 7), S42–S48. doi: 10.
1097/00005344-199001001-00006
Blier, P., de Montigny, C., and Chaput, Y. (1990). A role for the serotonin system
in the mechanism of action of antidepressant treatments: preclinical evidence.
J. Clin. Psychiatry 51(Suppl), 14–20. discussion: 21.
Boomsma, F., Bhaggoe, U. M., van der Houwen, A. M., and van den Meiracker,
A. H. (2003). Plasma semicarbazide-sensitive amine oxidase in human
(patho)physiology. Biochim. Biophys. Acta 1647, 48–54. doi: 10.1016/S1570-
9639(03)00047-5
Braak, H., and Del Tredici, K. (2011). The pathological process underlying
Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 121,
171–181. doi: 10.1007/s00401-010-0789-4
Bronstein, J. M., Tagliati, M., Alterman, R. L., Lozano, A. M., Volkmann, J.,
Stefani, A., et al. (2011). Deep brain stimulation for Parkinson disease: an
expert consensus and review of key issues. Arch. Neurol. 68, 165. doi: 10.1001/
archneurol.2010.260
Brown, W. A., and Rosdolsky, M. (2015). The clinical discovery of imipramine.
Am. J. Psychiatry 172, 426–429. doi: 10.1176/appi.ajp.2015.14101336
Buckley, P. F., Miller, B. J., Lehrer, D. S., and Castle, D. J. (2009). Psychiatric
comorbidities and schizophrenia. Schizophr. Bull. 35, 383–402. doi: 10.1093/
schbul/sbn135
Bunney, B. S., Aghajanian, G. K., and Roth, R. H. (1973). Comparison of effects
of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic
neurones. Nat. New Biol. 245, 123–125. doi: 10.1038/newbio245123a0
Burke, R. E., and O’Malley, K. (2013). Axon degeneration in Parkinson’s disease.
Exp. Neurol. 246, 72–83. doi: 10.1016/j.expneurol.2012.01.011
Butini, S., Nikolic, K., Kassel, S., Brückmann, H., Filipic, S., Agbaba, D., et al.
(2016). Polypharmacology of dopamine receptor ligands. Prog. Neurobiol. 142,
68–103. doi: 10.1016/j.pneurobio.2016.03.011
Carboni, E., Acquas, E., Frau, R., and Di Chiara, G. (1989). Differential inhibitory
effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release.
Eur. J. Pharmacol. 164, 515–519. doi: 10.1016/0014-2999(89)90259-8
Cardamone, L., Salzberg, M. R., O’Brien, T. J., and Jones, N. C. (2013).
Antidepressant therapy in epilepsy: can treating the comorbidities affect the
underlying disorder? Br. J. Pharmacol. 168, 1531–1554. doi: 10.1111/bph.12052
Carlsson, A., and Lindqvist, M. (1963). Effect of chlorpromazine or haloperidol
on formation of 3-methoxytyramine and normetanephrine in mouse brain.
Acta Pharmacol. Toxicol. (Copenh). 20, 140–144. doi: 10.1111/j.1600-0773.
1963.tb01730.x
Carruba, M. O., Mantegazza, P., Memo, M., Missale, C., Pizzi, M., and Spano, P. F.
(1986). Peripheral and central mechanisms of action of serotoninergic anorectic
drugs. Appetite 7(Suppl.), 105–113. doi: 10.1016/S0195-6663(86)80056-3
Carta, M., Carlsson, T., Kirik, D., and Björklund, A. (2007). Dopamine
released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in
parkinsonian rats. Brain 130(Pt 7), 1819–1833. doi: 10.1093/brain/awm082
Chang, A., and Fox, S. H. (2016). Psychosis in Parkinson’s disease: epidemiology,
pathophysiology, and management.Drugs 76, 1093–1118. doi: 10.1007/s40265-
016-0600-5
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill,
R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation
antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746–758.
doi: 10.1016/S0140-6736(09)60046-5
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan,
A., et al. (2011). Serotonin signaling is associated with lower amyloid-beta levels
and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108,
14968–14973. doi: 10.1073/pnas.1107411108
Citrome, L. (2013). Cariprazine: chemistry, pharmacodynamics,
pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Expert Opin. Drug Metab. Toxicol. 9, 193–206. doi: 10.1517/17425255.2013.
759211
Citrome, L. (2015). The ABC’s of dopamine receptor partial agonists - aripiprazole,
brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Int. J. Clin. Pract. 69, 1211–1220. doi: 10.1111/ijcp.12752
Claeysen, S., Bockaert, J., and Giannoni, P. (2015). Serotonin: a new hope
in Alzheimer’s disease? ACS Chem. Neurosci. 6, 940–943. doi: 10.1021/
acschemneuro.5b00135
Clineschmidt, B. V., and Lotti, V. J. (1973). Histamine: intraventricular injection
suppresses ingestive behavior of the cat. Arch. Int. Pharmacodyn. Ther. 206,
288–298.
Combarros, O., Warden, D. R., Hammond, N., Cortina-Borja, M., Belbin, O.,
Lehmann, M. G., et al. (2010). The dopamine beta-hydroxylase -1021C/T
polymorphism is associated with the risk of Alzheimer’s disease in the Epistasis
Project. BMCMed. Genet. 11:162. doi: 10.1186/1471-2350-11-162
Conklin, D. J., Langford, S. D., and Boor, P. J. (1998). Contribution of serum
and cellular semicarbazide-sensitive amine oxidase to amine metabolism and
cardiovascular toxicity. Toxicol. Sci. 46, 386–392. doi: 10.1093/toxsci/46.2.386
Cooper, J. R., Bloom, F. E., and Roth, R. H. (2003). The Biochemical Basis of
Neuropharmacology. New York, NY: Oxford University Press.
Cotzias, G. C. (1968). L-Dopa for Parkinsonism. N. Engl. J. Med. 278, 630. doi: 10.
1056/NEJM196803142781127
Cotzias, G. C., Papavasiliou, P. S., and Gellene, R. (1969). Modification of
Parkinsonism–chronic treatment with L-dopa. N. Engl. J. Med. 280, 337–345.
doi: 10.1056/NEJM196902132800701
Coulter, D. A., and Steinhäuser, C. (2015). Role of astrocytes in epilepsy. Cold
Spring Harb. Perspect. Med. 5:a022434. doi: 10.1101/cshperspect.a022434
Cremers, T. I., Giorgetti, M., Bosker, F. J., Hogg, S., Arnt, J., Mørk, A., et al. (2004).
Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin
reuptake blockade. Neuropsychopharmacology 29, 1782–1789. doi: 10.1038/sj.
npp.1300474
Cremers, T. I., Rea, K., Bosker, F. J., Wikström, H. V., Hogg, S., Mørk, A., et al.
(2007). Augmentation of SSRI effects on serotonin by 5-HT2C antagonists:
mechanistic studies. Neuropsychopharmacology 32, 1550–1557. doi: 10.1038/sj.
npp.1301287
Cryan, J. F., Page, M. E., and Lucki, I. (2002). Noradrenergic lesions differentially
alter the antidepressant-like effects of reboxetine in amodified forced swim test.
Eur. J. Pharmacol. 436, 197–205. doi: 10.1016/S0014-2999(01)01628-4
Cryan, J. F., Valentino, R. J., and Lucki, I. (2005). Assessing substrates underlying
the behavioral effects of antidepressants using the modified rat forced
swimming test. Neurosci. Biobehav. Rev. 29, 547–569. doi: 10.1016/j.neubiorev.
2005.03.008
Curet, O., Damoiseau-Ovens, G., Sauvage, C., Sontag, N., Avenet, P., Depoortere,
H., et al. (1998). Preclinical profile of befloxatone, a new reversible MAO-
A inhibitor. J. Affect. Disord. 51, 287–303. doi: 10.1016/S0165-0327(98)
00225-0
Dale, E., Bang-Andersen, B., and Sánchez, C. (2015). Emerging mechanisms and
treatments for depression beyond SSRIs and SNRIs. Biochem. Pharmacol. 95,
81–97. doi: 10.1016/j.bcp.2015.03.011
Davidson, J. R. T. (2003). Pharmacotherapy of social phobia.Acta. Psychiatr. Scand.
Suppl. 108, 65–71. doi: 10.1034/j.1600-0447.108.s417.7.x
Daws, L. C. (2009). Unfaithful neurotransmitter transporters: focus on serotonin
uptake and implications for antidepressant efficacy. Pharmacol. Ther. 121,
89–99. doi: 10.1016/j.pharmthera.2008.10.004
De Deurwaerdère, P. (2016). Cariprazine: new dopamine biased agonist for
neuropsychiatric disorders. Drugs Today 52, 97–110. doi: 10.1358/dot.2016.52.
2.2461868
De Deurwaerdère, P., and Di Giovanni, G. (2016). Serotonergic modulation of
the activity of mesencephalic dopaminergic systems: therapeutic implications.
Prog. Neurobiol. doi: 10.1016/j.pneurobio.2016.03.004. [Epub ahead of print].
De Deurwaerdère, P., Di Giovanni, G., and Millan, M. J. (2016). Expanding
the repertoire of L-DOPA’s actions: a comprehensive review of its functional
neurochemistry. Prog. Neurobiol. doi: 10.1016/j.pneurobio.2016.07.002. [Epub
ahead of print].
De Deurwaerdère, P., and Ding, Y. (2016). Antiparkinsonian treatment for
depression in Parkinson’s disease: are selective serotonin reuptake inhibitors
recommended? Transl. Neurosci. Clin. 2, 138–149. doi: 10.18679/CN11-6030/
R.2016.019
De Deurwaerdère, P., Lagière, M., Bosc, M., and Navailles, S. (2013). Multiple
controls exerted by 5-HT2C receptors upon basal ganglia function: from
Frontiers in Neuroscience | www.frontiersin.org 20 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
physiology to pathophysiology. Exp. Brain Res. 230, 477–511. doi: 10.1007/
s00221-013-3508-2
de la Fuente-Fernández, R. (2013). Imaging of dopamine in PD and implications
for motor and neuropsychiatric manifestations of PD. Front. Neurol. 4:90.
doi: 10.3389/fneur.2013.00090
de la Fuente-Fernández, R., Schulzer, M., Mak, E., Calne, D. B., and Stoessl, A. J.
(2004). Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a
probabilistic model. Brain 127(Pt 4), 888–899. doi: 10.1093/brain/awh102
Delaville, C., Chetrit, J., Abdallah, K., Morin, S., Cardoit, L., De Deurwaerdère, P.,
et al. (2012). Emerging dysfunctions consequent to combined monoaminergic
depletions in Parkinsonism. Neurobiol. Dis. 45, 763–773. doi: 10.1016/j.nbd.
2011.10.023
Delaville, C., Deurwaerdère, P. D., and Benazzouz, A. (2011). Noradrenaline and
Parkinson’s disease. Front. Syst. Neurosci. 5:31. doi: 10.3389/fnsys.2011.00031
Delgado, P. L., and Moreno, F. A. (2000). Role of norepinephrine in depression. J.
Clin. Psychiatry 61(Suppl. 1), 5–12.
del Mar Hernandez, M., Esteban, M., Szabo, P., Boada, M., and Unzeta, M. (2005).
Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid
protein and aging. Neurosci. Lett. 384, 183–187. doi: 10.1016/j.neulet.2005.04.
074
Del Tredici, K., Rüb, U., De Vos, R. A., Bohl, J. R., and Braak, H. (2002). Where
does parkinson disease pathology begin in the brain? J. Neuropathol. Exp.
Neurol. 61, 413–426. doi: 10.1093/jnen/61.5.413
Deroche-Gamonet, V., Belin, D., and Piazza, P. V. (2004). Evidence for addiction-
like behavior in the rat. Science 305, 1014–1017. doi: 10.1126/science.10
99020
Deutch, A. Y., Moghaddam, B., Innis, R. B., Krystal, J. H., Aghajanian, G. K.,
Bunney, B. S., et al. (1991). Mechanisms of action of atypical antipsychotic
drugs. Implications for novel therapeutic strategies for schizophrenia.
Schizophr. Res 4, 121–156. doi: 10.1016/0920-9964(91)90030-U
Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., and Rogawski, M. A.
(2013). Glia and epilepsy: excitability and inflammation. Trends Neurosci. 36,
174–184. doi: 10.1016/j.tins.2012.11.008
Devroye, C., Cathala, A., Haddjeri, N., Rovera, R., Vallée, M., Drago, F., et al.
(2016). Differential control of dopamine ascending pathways by serotonin2B
receptor antagonists: new opportunities for the treatment of schizophrenia.
Neuropharmacology 109, 59–68. doi: 10.1016/j.neuropharm.2016.
05.024
Dias, K. S., and Viegas, C. Jr. (2014). Multi-target directed drugs: a modern
approach for design of new drugs for the treatment of alzheimer’s disease. Curr.
Neuropharmacol. 12, 239–255. doi: 10.2174/1570159X1203140511153200
Di Chiara, G. (1992). Reinforcing drug seeking. Trends Pharmacol. Sci. 13,
428–429. doi: 10.1016/0165-6147(92)90135-S
Di Chiara, G., and Imperato, A. (1988). Drugs abused by humans preferentially
increase synaptic dopamine concentrations in the mesolimbic system of freely
moving rats. Proc. Natl. Acad. Sci. U.S.A. 85, 5274–5278. doi: 10.1073/pnas.85.
14.5274
Di Chiara, G., Tanda, G. L., Frau, R., and Carboni, E. (1992). Heterologous
monoamine reuptake: lack of transmitter specificity of neuron-specific carriers.
Neurochem. Int. 20(Suppl.), 231s–235s.
Di Giovanni, G., and De Deurwaerdère, P. (2016). New therapeutic opportunities
for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacol. Ther.
157, 125–162. doi: 10.1016/j.pharmthera.2015.11.009
Di Giovanni, S., Eleuteri, S., Paleologou, K. E., Yin, G., Zweckstetter,M., Carrupt, P.
A., et al. (2010). Entacapone and tolcapone, two catechol O-methyltransferase
inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and
protect against amyloid-induced toxicity. J. Biol. Chem. 285, 14941–14954.
doi: 10.1074/jbc.M109.080390
DiNapoli, V. A., Huber, J. D., Houser, K., Li, X., and Rosen, C. L. (2008). Early
disruptions of the blood-brain barrier may contribute to exacerbated neuronal
damage and prolonged functional recovery following stroke in aged rats.
Neurobiol. Aging 29, 753–764. doi: 10.1016/j.neurobiolaging.2006.12.007
Durif, F., Vidailhet, M., Bonnet, A. M., Blin, J., and Agid, Y. (1995). Levodopa-
induced dyskinesias are improved by fluoxetine. Neurology 45, 1855–1858.
doi: 10.1212/WNL.45.10.1855
Ebadi, M., and Srinivasan, S. K. (1995). Pathogenesis, prevention, and treatment of
neuroleptic-induced movement disorders. Pharmacol. Rev. 47, 575–604.
Eisenhofer, G., Kopin, I. J., and Goldstein, D. S. (2004). Catecholamine
metabolism: a contemporary view with implications for physiology and
medicine. Pharmacol. Rev. 56, 331–349. doi: 10.1124/pr.56.3.1
Elrod, R., Peskind, E. R., DiGiacomo, L., Brodkin, K. I., Veith, R. C., and Raskind,
M. A. (1997). Effects of Alzheimer’s disease severity on cerebrospinal fluid
norepinephrine concentration. Am. J. Psychiatry 154, 25–30. doi: 10.1176/ajp.
154.1.25
Emilien, G., Maloteaux, J. M., Geurts, M., Hoogenberg, K., and Cragg, S. (1999).
Dopamine receptors–physiological understanding to therapeutic intervention
potential. Pharmacol. Ther. 84, 133–156. doi: 10.1016/S0163-7258(99)00029-7
Esbenshade, T. A., Fox, G. B., and Cowart, M. D. (2006). Histamine H3 receptor
antagonists: preclinical promise for treating obesity and cognitive disorders.
Mol. Interv. 6, 77–88, 59. doi: 10.1124/mi.6.2.5
Fakhfouri, G., Mousavizadeh, K., Mehr, S. E., Dehpour, A. R., Zirak, M. R., Ghia,
J. E., et al. (2015). From chemotherapy-induced emesis to neuroprotection:
therapeutic opportunities for 5-HT3 receptor antagonists. Mol. Neurobiol. 52,
1670–1679. doi: 10.1007/s12035-014-8957-5
Fakhfouri, G., Rahimian, R., Ghia, J. E., Khan, W. I., and Dehpour, A. R. (2012).
Impact of 5-HT(3) receptor antagonists on peripheral and central diseases.
Drug Discov. Today 17, 741–747. doi: 10.1016/j.drudis.2012.02.009
Fangmann, P., Assion, H. J., Juckel, G., González, C. A., and López-Muñoz, F.
(2008). Half a century of antidepressant drugs: on the clinical introduction
of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II:
tricyclics and tetracyclics. J. Clin. Psychopharmacol. 28, 1–4. doi: 10.1097/jcp.
0b013e3181627b60
Ferrer, I., Lizcano, J. M., Hernández, M., and Unzeta, M. (2002). Overexpression of
semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients
with Alzheimer’s disease and cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy. Neurosci. Lett. 321, 21–24.
doi: 10.1016/S0304-3940(01)02465-X
Fidalgo, C., Ko,W. K., Tronci, E., Li, Q., Stancampiano, R., Chuan, Q., et al. (2015).
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in
animal models of Parkinson’s disease. Neuroscience 298, 389–396. doi: 10.1016/
j.neuroscience.2015.04.027
Filip, V., and Kolibás, E. (1999). Selegiline in the treatment of Alzheimer’s
disease: a long-term randomized placebo-controlled trial. Czech and Slovak
Senile Dementia of Alzheimer type study group. J. Psychiatry Neurosci. 24,
234–243.
Finberg, J. P. (2014). Update on the pharmacology of selective inhibitors of MAO-
A and MAO-B: focus on modulation of CNS monoamine neurotransmitter
release. Pharmacol. Ther. 143, 133–152. doi: 10.1016/j.pharmthera.2014.
02.010
Fisher, A., Biggs, C. S., Eradiri, O., and Starr, M. S. (2000). Dual effects of L-3,4-
dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine
release and motor stimulation in the reserpine-treated rat: evidence that
behaviour is dopamine independent. Neuroscience 95, 97–111. doi: 10.1016/
S0306-4522(99)00406-6
Fitoussi, A., Dellu-Hagedorn, F., and De Deurwaerdère, P. (2013). Monoamines
tissue content analysis reveals restricted and site-specific correlations in brain
regions involved in cognition. Neuroscience 255, 233–245. doi: 10.1016/j.
neuroscience.2013.09.059
Fitzgerald, D. H., and Tipton, K. F. (2002). Inhibition of monoamine oxidase
modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO). J.
Neural Transm. (Vienna) 109, 251–265. doi: 10.1007/s007020200021
Fletcher, P. J., and Higgins, G. A. (2011). “Serotonin and reward-related behaviour:
focus on 5-HT2C receptors,” in 5-HT2C Receptors in the Pathophysiology of CNS
Disease, eds G. Di Giovanni, E. Esposito, and V. Di Matteo (New York, NY:
Springer), 293–324. doi: 10.1007/978-1-60761-941-3_15
Fornito, A., and Bullmore, E. T. (2015). Connectomics: a new paradigm for
understanding brain disease. Eur. Neuropsychopharmacol. 25, 733–748. doi: 10.
1016/j.euroneuro.2014.02.011
Fowler, J. S., MacGregor, R. R., Wolf, A. P., Arnett, C. D., Dewey, S. L., Schlyer,
D., et al. (1987). Mapping human brain monoamine oxidase A and B with
11C-labeled suicide inactivators and PET. Science 235, 481–485. doi: 10.1126/
science.3099392
Fox, S. H. (2013). Non-dopaminergic treatments for motor control in Parkinson’s
disease. Drugs 73, 1405–1415. doi: 10.1007/s40265-013-0105-4
Frontiers in Neuroscience | www.frontiersin.org 21 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Friedman, J. H., and Factor, S. A. (2000). Atypical antipsychotics in the treatment
of drug-induced psychosis in Parkinson’s disease. Mov. Disord. 15, 201–211.
doi: 10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D
Gagnon, C., Schatz, R., Otten, U., and Thoenen, H. (1976). Synthesis, subcellular
distribution and turnover of dopamine beta-hydroxylase in organ cultures
of sympathetic ganglia and adrenal medullae. J. Neurochem. 27, 1083–1089.
doi: 10.1111/j.1471-4159.1976.tb00312.x
Galati, S., and Di Giovanni, G. (2010). Neuroprotection in Parkinson’s disease: a
realistic goal? CNS Neurosci. Ther. 16, 327–329. doi: 10.1111/j.1755-5949.2010.
00206.x
Garattini, S. (1995). Biological actions of drugs affecting serotonin and eating.
Obes. Res. 3(Suppl. 4), 463s–470s. doi: 10.1002/j.1550-8528.1995.tb00213.x
Garcia-Alloza, M., Gil-Bea, F. J., Diez-Ariza, M., Chen, C. P., Francis, P. T.,
Lasheras, B., et al. (2005). Cholinergic-serotonergic imbalance contributes to
cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia
43, 442–449. doi: 10.1016/j.neuropsychologia.2004.06.007
Garcia-Alloza, M., Hirst, W. D., Chen, C. P., Lasheras, B., Francis, P. T., and
Ramírez, M. J. (2004). Differential involvement of 5-HT(1B/1D) and 5-HT6
receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease.
Neuropsychopharmacology 29, 410–416. doi: 10.1038/sj.npp.1300330
Gardier, A. M., David, D. J., Jego, G., Przybylski, C., Jacquot, C., Durier, S., et al.
(2003). Effects of chronic paroxetine treatment on dialysate serotonin in 5-
HT1B receptor knockout mice. J. Neurochem. 86, 13–24. doi: 10.1046/j.1471-
4159.2003.01827.x
Gbahou, F., Davenas, E., Morisset, S., and Arrang, J. M. (2010). Effects of
betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro
and partial inverse agonism in vivo. J. Pharmacol. Exp. Ther. 334, 945–954.
doi: 10.1124/jpet.110.168633
Geldenhuys, W. J., and Van der Schyf, C. J. (2011). Role of serotonin in Alzheimer’s
disease: a new therapeutic target? CNS Drugs 25, 765–781. doi: 10.2165/
11590190-000000000-00000
Ghanemi, A., and Hu, X. (2015). Elements toward novel therapeutic targeting of
the adrenergic system. Neuropeptides 49, 25–35. doi: 10.1016/j.npep.2014.11.
003
Grammas, P. (2011). Neurovascular dysfunction, inflammation and endothelial
activation: implications for the pathogenesis of Alzheimer’s disease. J.
Neuroinflammation 8:26. doi: 10.1186/1742-2094-8-26
Greendyke, R. M., Kanter, D. R., Schuster, D. B., Verstreate, S., and Wootton, J.
(1986). Propranolol treatment of assaultive patients with organic brain disease.
A double-blind crossover, placebo-controlled study. J. Nerv. Ment. Dis. 174,
290–294. doi: 10.1097/00005053-198605000-00005
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., and Mesulam, M. M.
(2007). Locus coeruleus neurofibrillary degeneration in aging, mild cognitive
impairment and early Alzheimer’s disease. Neurobiol. Aging 28, 327–335.
doi: 10.1016/j.neurobiolaging.2006.02.007
Guglielmotto, M., Aragno, M., Autelli, R., Giliberto, L., Novo, E., Colombatto, S.,
et al. (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic
injury: role of oxidative stress and HIF1alpha. J. Neurochem. 108, 1045–1056.
doi: 10.1111/j.1471-4159.2008.05858.x
Guiard, B. P., Froger, N., Hamon, M., Gardier, A. M., and Lanfumey, L. (2005).
Sustained pharmacological blockade of NK1 substance P receptors causes
functional desensitization of dorsal raphe 5-HT 1A autoreceptors in mice. J.
Neurochem. 95, 1713–1723. doi: 10.1111/j.1471-4159.2005.03488.x
Guidi, I., Galimberti, D., Lonati, S., Novembrino, C., Bamonti, F., Tiriticco,
M., et al. (2006). Oxidative imbalance in patients with mild cognitive
impairment and Alzheimer’s disease. Neurobiol. Aging 27, 262–269. doi: 10.
1016/j.neurobiolaging.2005.01.001
Gumnick, J. F., and Nemeroff, C. B. (2000). Problems with currently available
antidepressants. J. Clin. Psychiatry 61(Suppl. 10), 5–15.
Gururajan, A., Clarke, G., Dinan, T. G., and Cryan, J. F. (2016). Molecular
biomarkers of depression. Neurosci. Biobehav. Rev. 64, 101–133. doi: 10.1016/j.
neubiorev.2016.02.011
Gustafson, A., King, C., and Rey, J. A. (2013). Lorcaserin (Belviq): A selective
serotonin 5-HT2C agonist in the treatment of obesity. P T 38, 525–534.
Haefely, W., Burkard, W. P., Cesura, A. M., Kettler, R., Lorez, H. P., Martin,
J. R., et al. (1992). Biochemistry and pharmacology of moclobemide, a
prototype RIMA. Psychopharmacology (Berl). 106(Suppl.), S6–S14. doi: 10.
1007/BF02246225
Hale, M. W., and Lowry, C. A. (2011). Functional topography of midbrain
and pontine serotonergic systems: implications for synaptic regulation of
serotonergic circuits. Psychopharmacology (Berl). 213, 243–264. doi: 10.1007/
s00213-010-2089-z
Hamon, M., and Blier, P. (2013). Monoamine neurocircuitry in depression and
strategies for new treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 45,
54–63. doi: 10.1016/j.pnpbp.2013.04.009
Han, C., Wang, S. M., Kato, M., Lee, S. J., Patkar, A. A., Masand, P. S., et al.
(2013). Second-generation antipsychotics in the treatment of major depressive
disorder: current evidence. Expert Rev. Neurother. 13, 851–870. doi: 10.1586/
14737175.2013.811901
Harden, D. G., and Grace, A. A. (1995). Activation of dopamine cell firing by
repeated L-DOPA administration to dopamine-depleted rats: its potential role
in mediating the therapeutic response to L-DOPA treatment. J. Neurosci. 15,
6157–6166.
Haslam, D. (2016). Weight management in obesity - past and present. Int. J. Clin.
Pract. 70, 206–217. doi: 10.1111/ijcp.12771
Hauser, R. A., Abler, V., Eyal, E., and Eliaz, R. E. (2016). Efficacy of rasagiline
in early Parkinson’s disease: a meta-analysis of data from the TEMPO and
ADAGIO studies. Int. J. Neurosci. 126, 942–946. doi: 10.3109/00207454.2016.
1154552
Hawirko, L., and Sprague, P. H. (1946). Appetite-depressing drugs in obesity. Can.
Med. Assoc. J. 54, 26–29.
Heneka, M. T., Galea, E., Gavriluyk, V., Dumitrescu-Ozimek, L., Daeschner, J.,
O’Banion, M. K., et al. (2002). Noradrenergic depletion potentiates beta -
amyloid-induced cortical inflammation: implications for Alzheimer’s disease.
J. Neurosci. 22, 2434–2442.
Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-
Ozimek, L., Terwel, D., et al. (2010). Locus ceruleus controls Alzheimer’s disease
pathology by modulating microglial functions through norepinephrine. Proc.
Natl. Acad. Sci. U.S.A. 107, 6058–6063. doi: 10.1073/pnas.0909586107
Hensler, J. G., Artigas, F., Bortolozzi, A., Daws, L. C., De Deurwaerdère, P., Milan,
L., et al. (2013). Catecholamine/Serotonin interactions: systems thinking for
brain function and disease. Adv. Pharmacol. 68, 167–197. doi: 10.1016/B978-
0-12-411512-5.00009-9
Hernandez-Guillamon, M., Garcia-Bonilla, L., Solé, M., Sosti, V., Parés,
M., Campos, M., et al. (2010). Plasma VAP-1/SSAO activity predicts
intracranial hemorrhages and adverse neurological outcome after tissue
plasminogen activator treatment in stroke. Stroke 41, 1528–1535. doi: 10.1161/
STROKEAHA.110.584623
Hernandez-Guillamon, M., Solé, M., Delgado, P., García-Bonilla, L., Giralt, D.,
Boada, C., et al. (2012). VAP-1/SSAO plasma activity and brain expression
in human hemorrhagic stroke. Cerebrovasc. Dis. 33, 55–63. doi: 10.1159/
000333370
Higgins, G. A., and Fletcher, P. J. (2015). Therapeutic potential of 5-ht2c receptor
agonists for addictive disorders. ACS Chem. Neurosci. 6, 1071–1088. doi: 10.
1021/acschemneuro.5b00025
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., et al.
(2011). Apomorphine treatment in Alzheimer mice promoting amyloid-beta
degradation. Ann. Neurol. 69, 248–256. doi: 10.1002/ana.22319
Hiranita, T., Kohut, S. J., Soto, P. L., Tanda, G., Kopajtic, T. A., and Katz, J. L.
(2014). Preclinical efficacy of N-substituted benztropine analogs as antagonists
of methamphetamine self-administration in rats. J. Pharmacol. Exp. Ther. 348,
174–191. doi: 10.1124/jpet.113.208264
Holm, P., Ettrup, A., Klein, A. B., Santini, M. A., El-Sayed, M., Elvang, A. B., et al.
(2010). Plaque deposition dependent decrease in 5-HT2A serotonin receptor
in AbetaPPswe/PS1dE9 amyloid overexpressing mice. J. Alzheimers. Dis. 20,
1201–1213. doi: 10.3233/JAD-2010-100117
Howell, L. L., and Cunningham, K. A. (2015). Serotonin 5-HT2 receptor
interactions with dopamine function: implications for therapeutics in
cocaine use disorder. Pharmacol. Rev. 67, 176–197. doi: 10.1124/pr.114.
009514
Hoyer, D., Hannon, J. P., and Martin, G. R. (2002). Molecular, pharmacological
and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71,
533–554. doi: 10.1016/S0091-3057(01)00746-8
Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors
in the pathogenesis of dementia. Acta Neuropathol. 120, 287–296. doi: 10.1007/
s00401-010-0718-6
Frontiers in Neuroscience | www.frontiersin.org 22 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Iadecola, C., and Anrather, J. (2011). The immunology of stroke: frommechanisms
to translation. Nat. Med. 17, 796–808. doi: 10.1038/nm.2399
Iderberg, H., McCreary, A. C., Varney, M. A., Kleven, M. S., Koek, W., Bardin, L.,
et al. (2015). NLX-112, a novel 5-HT1A receptor agonist for the treatment of
L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Exp.
Neurol. 271, 335–350. doi: 10.1016/j.expneurol.2015.05.021
Invernizzi, R., Belli, S., and Samanin, R. (1992). Citalopram’s ability to increase
the extracellular concentrations of serotonin in the dorsal raphe prevents the
drug’s effect in the frontal cortex. Brain Res. 584, 322–324. doi: 10.1016/0006-
8993(92)90914-U
Invernizzi, R., Bramante, M., and Samanin, R. (1996). Role of 5-HT1A receptors
in the effects of acute chronic fluoxetine on extracellular serotonin in the
frontal cortex. Pharmacol. Biochem. Behav. 54, 143–147. doi: 10.1016/0091-
3057(95)02159-0
Ittner, L. M., and Götz, J. (2011). Amyloid-beta and tau–a toxic pas de deux in
Alzheimer’s disease. Nat. Rev. Neurosci. 12, 65–72. doi: 10.1038/nrn2967
Iversen, L. L., Rossor, M. N., Reynolds, G. P., Hills, R., Roth, M., Mountjoy, C.
Q., et al. (1983). Loss of pigmented dopamine-beta-hydroxylase positive cells
from locus coeruleus in senile dementia of Alzheimer’s type. Neurosci. Lett. 39,
95–100. doi: 10.1016/0304-3940(83)90171-4
Jackson, H. C., Bearham, M. C., Hutchins, L. J., Mazurkiewicz, S. E., Needham,
A. M., and Heal, D. J. (1997). Investigation of the mechanisms underlying
the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor,
sibutramine, in the rat. Br. J. Pharmacol. 121, 1613–1618. doi: 10.1038/sj.bjp.
0701311
Jacquot, C., David, D. J., Gardier, A. M., and Sánchez, C. (2007). [Escitalopram and
citalopram: the unexpected role of the R-enantiomer]. Encephale 33, 179–187.
doi: 10.1016/S0013-7006(07)91548-1
Jalkanen, S., and Salmi, M. (2008). VAP-1 and CD73, endothelial cell surface
enzymes in leukocyte extravasation. Arterioscler. Thromb. Vasc. Biol. 28, 18–26.
doi: 10.1161/ATVBAHA.107.153130
James, W. P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., et al.
(2000). Effect of sibutramine on weight maintenance after weight loss: a
randomised trial. STORM Study Group. Sibutramine trial of obesity reduction
and maintenance. Lancet 356, 2119–2125. doi: 10.1016/S0140-6736(00)03491-
7
Jellinger, K. A. (1991). Pathology of Parkinson’s disease. Changes other than the
nigrostriatal pathway. Mol. Chem. Neuropathol. 14, 153–197. doi: 10.1007/
BF03159935
Jenner, P. (2004). Preclinical evidence for neuroprotection with monoamine
oxidase-B inhibitors in Parkinson’s disease. Neurology 63(7 Suppl 2), S13–S22.
doi: 10.1212/wnl.63.7_suppl_2.s13
Jobe, P. C., and Browning, R. A. (2005). The serotonergic and noradrenergic effects
of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav.
7, 602–619. doi: 10.1016/j.yebeh.2005.07.014
Joyce, J. N., Smutzer, G., Whitty, C. J., Myers, A., and Bannon, M. J.
(1997). Differential modification of dopamine transporter and tyrosine
hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with
parkinsonism, and Alzheimer’s disease.Mov. Disord. 12, 885–897. doi: 10.1002/
mds.870120609
Kalaria, R. N., and Andorn, A. C. (1991). Adrenergic receptors in aging and
Alzheimer’s disease: decreased alpha 2-receptors demonstrated by [3H]p-
aminoclonidine binding in prefrontal cortex. Neurobiol. Aging 12, 131–136.
doi: 10.1016/0197-4580(91)90051-K
Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., and Feinstein, D.
L. (2012). The noradrenaline precursor L-DOPS reduces pathology in a mouse
model of Alzheimer’s disease. Neurobiol. Aging 33, 1651–1663. doi: 10.1016/j.
neurobiolaging.2011.04.012
Kapur, S., and Remington, G. (1996). Serotonin-dopamine interaction and its
relevance to schizophrenia. Am. J. Psychiatry 153, 466–476. doi: 10.1176/ajp.
153.4.466
Kapur, S., and Seeman, P. (2001). Does fast dissociation from the dopamine d(2)
receptor explain the action of atypical antipsychotics?: A new hypothesis. Am.
J. Psychiatry 158, 360–369. doi: 10.1176/appi.ajp.158.3.360
Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade
hypothesis for Alzheimer’s disease: an appraisal for the development of
therapeutics. Nat. Rev. Drug Discov. 10, 698–712. doi: 10.1038/nrd3505
Kasper, S., Corruble, E., Hale, A., Lemoine, P., Montgomery, S. A., and
Quera-Salva, M. A. (2013). Antidepressant efficacy of agomelatine versus
SSRI/SNRI: results from a pooled analysis of head-to-head studies without
a placebo control. Int. Clin. Psychopharmacol. 28, 12–19. doi: 10.1097/YIC.
0b013e328359768e
Kepe, V., Barrio, J. R., Huang, S. C., Ercoli, L., Siddarth, P., Shoghi-Jadid,
K., et al. (2006). Serotonin 1A receptors in the living brain of Alzheimer’s
disease patients. Proc. Natl. Acad. Sci. U.S.A. 103, 702–707. doi: 10.1073/pnas.
0510237103
Kiloh, L. G., and Brandon, S. (1962). Habituation and addiction to amphetamines.
Br. Med. J. 2, 40–43. doi: 10.1136/bmj.2.5296.40
Kiss, B., Horváth, A., Némethy, Z., Schmidt, E., Laszlovszky, I., Bugovics, G.,
et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring,
D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic
candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333,
328–340. doi: 10.1124/jpet.109.160432
Koch, G., Di Lorenzo, F., Bonnì, S., Giacobbe, V., Bozzali, M., Caltagirone, C., et al.
(2014). Dopaminergic modulation of cortical plasticity in Alzheimer’s disease
patients. Neuropsychopharmacology 39, 2654–2661. doi: 10.1038/npp.2014.119
Koob, G. F. (1992). Drugs of abuse: anatomy, pharmacology and function of
reward pathways. Trends Pharmacol. Sci. 13, 177–184. doi: 10.1016/0165-
6147(92)90060-J
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E.,
et al. (2014). Addiction as a stress surfeit disorder.Neuropharmacology 76(Pt B),
370–382. doi: 10.1016/j.neuropharm.2013.05.024
Koob, G. F., and Le Moal, M. (1997). Drug abuse: hedonic homeostatic
dysregulation. Science 278, 52–58. doi: 10.1126/science.278.5335.52
Koob, G. F., and Le Moal, M. (2008). Review. Neurobiological mechanisms for
opponent motivational processes in addiction. Philos. Trans. R. Soc. Lond. B.
Biol. Sci. 363, 3113–3123. doi: 10.1098/rstb.2008.0094
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg,
S., Ernsberger, P., et al. (2003). H1-histamine receptor affinity predicts
short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology 28, 519–526. doi: 10.1038/sj.npp.1300027
Kuczenski, R., Segal, D. S., Cho, A. K., and Melega, W. (1995). Hippocampus
norepinephrine, caudate dopamine and serotonin, and behavioral responses
to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 15,
1308–1317.
Kumar, U., and Patel, S. C. (2007). Immunohistochemical localization of dopamine
receptor subtypes (D1R-D5R) in Alzheimer’s disease brain. Brain Res. 1131,
187–196. doi: 10.1016/j.brainres.2006.10.049
Kurkijärvi, R., Adams, D. H., Leino, R., Möttönen, T., Jalkanen, S., and Salmi,
M. (1998). Circulating form of human vascular adhesion protein-1 (VAP-
1): increased serum levels in inflammatory liver diseases. J. Immunol. 161,
1549–1557.
Lai, M. K., Tsang, S. W., Alder, J. T., Keene, J., Hope, T., Esiri, M. M., et al.
(2005). Loss of serotonin 5-HT2A receptors in the postmortem temporal
cortex correlates with rate of cognitive decline in Alzheimer’s disease.
Psychopharmacology (Berl). 179, 673–677. doi: 10.1007/s00213-004-2077-2
Lai, M. K., Tsang, S. W., Francis, P. T., Esiri, M. M., Hope, T., Lai, O. F.,
et al. (2003). [3H]GR113808 binding to serotonin 5-HT4 receptors in the
postmortem neocortex of Alzheimer disease: a clinicopathological study. J.
Neural Transm. (Vienna) 110, 779–788. doi: 10.1007/s00702-003-0825-9
Lanari, A., Amenta, F., Silvestrelli, G., Tomassoni, D., and Parnetti, L. (2006).
Neurotransmitter deficits in behavioural and psychological symptoms of
Alzheimer’s disease.Mech. Ageing Dev. 127, 158–165. doi: 10.1016/j.mad.2005.
09.016
Lecklin, A., Etu-Seppälä, P., Stark, H., and Tuomisto, L. (1998). Effects of
intracerebroventricularly infused histamine and selective H1, H2 and H3
agonists on food and water intake and urine flow in Wistar rats. Brain Res. 793,
279–288. doi: 10.1016/S0006-8993(98)00186-3
Lees, A. J., Tolosa, E., and Olanow, C. W. (2015). Four pioneers of L-dopa
treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin
Yahr.Mov. Disord. 30, 19–36. doi: 10.1002/mds.26120
Leggio, G. M., Bucolo, C., Platania, C. B. M., Salomone, S., and Drago, F. (2016).
Current drug treatments targeting dopamine D3 receptor. Pharmacol. Ther.
165, 164–177. doi: 10.1016/j.pharmthera.2016.06.007
Frontiers in Neuroscience | www.frontiersin.org 23 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Leiser, S. C., Li, Y., Pehrson, A. L., Dale, E., Smagin, G., and Sanchez, C. (2015).
Serotonergic regulation of prefrontal cortical circuitries involved in cognitive
processing: a review of individual 5-HT receptor mechanisms and concerted
effects of 5-HT receptors exemplified by the multimodal antidepressant
vortioxetine. ACS Chem. Neurosci. 6, 970–986. doi: 10.1021/cn500340j
Le Moal, M., and Simon, H. (1991). Mesocorticolimbic dopaminergic network:
functional and regulatory roles. Physiol. Rev. 71, 155–234.
León, R., and Marco-Contelles, J. (2011). A step further towards multitarget drugs
for Alzheimer and neuronal vascular diseases: targeting the cholinergic system,
amyloid-beta aggregation and Ca(2+) dyshomeostasis. Curr. Med. Chem. 18,
552–576. doi: 10.2174/092986711794480186
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., et al.
(2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment:
a follow-up study. Neurology 69, 631–639. doi: 10.1212/01.wnl.0000267428.
62582.aa
Liu, H. C., Yang, J. C., Chang, Y. F., Liu, T. Y., and Chi, C. W. (1991). Analysis of
monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer’s
disease. Ann. N. Y. Acad. Sci. 640, 215–218. doi: 10.1111/j.1749-6632.1991.
tb00220.x
Liu, J., Dong, J., Wang, L., Su, Y., Yan, P., and Sun, S. (2013). Comparative
efficacy and acceptability of antidepressants in Parkinson’s disease: a network
meta-analysis. PLoS ONE 8:e76651. doi: 10.1371/journal.pone.0076651
Liu, L., Li, Q., Li, N., Ling, J., Liu, R., Wang, Y., et al. (2011). Simultaneous
determination of catecholamines and their metabolites related to Alzheimer’s
disease in human urine. J. Sep. Sci. 34, 1198–1204. doi: 10.1002/jssc.201000799
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A.,
et al. (2009). Long-term effects of the concomitant use of memantine with
cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatr.
80, 600–607. doi: 10.1136/jnnp.2008.158964
López-Muñoz, F., and Alamo, C. (2009). Monoaminergic neurotransmission: the
history of the discovery of antidepressants from 1950s until today.Curr. Pharm.
Des. 15, 1563–1586. doi: 10.2174/138161209788168001
López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., and Rubio, G.
(2005). History of the discovery and clinical introduction of chlorpromazine.
Ann. Clin. Psychiatry 17, 113–135. doi: 10.1080/10401230591002002
Lorke, D. E., Lu, G., Cho, E., and Yew, D. T. (2006). Serotonin 5-HT2A and 5-HT6
receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC
Neurosci. 7:36. doi: 10.1186/1471-2202-7-36
Lucas, G., and Debonnel, G. (2002). 5-HT4 receptors exert a frequency-related
facilitatory control on dorsal raphe nucleus 5-HT neuronal activity. Eur. J.
Neurosci. 16, 817–822. doi: 10.1046/j.1460-9568.2002.02150.x
Lucas, G., Rymar, V. V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., et al. (2007).
Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a
rapid onset of action. Neuron 55, 712–725. doi: 10.1016/j.neuron.2007.07.041
Luque, C. A., and Rey, J. A. (1999). Sibutramine: a serotonin-norepinephrine
reuptake-inhibitor for the treatment of obesity. Ann. Pharmacother. 33,
968–978. doi: 10.1345/aph.18319
Luscombe, G. P., Slater, N. A., Lyons, M. B., Wynne, R. D., Scheinbaum, M.
L., and Buckett, W. R. (1990). Effect on radiolabelled-monoamine uptake in
vitro of plasma taken from healthy volunteers administered the antidepressant
sibutramine HCl. Psychopharmacology (Berl). 100, 345–349. doi: 10.1007/
BF02244604
Marchesi, V. T. (2014). Alzheimer’s disease and CADASIL are heritable, adult-
onset dementias that both involve damaged small blood vessels. Cell. Mol. Life
Sci. 71, 949–955. doi: 10.1007/s00018-013-1542-7
Markham, A. (2016). Pimavanserin: first global approval. Drugs 76, 1053–1057.
doi: 10.1007/s40265-016-0597-9
Marner, L., Frokjaer, V. G., Kalbitzer, J., Lehel, S., Madsen, K., Baare, W. F., et al.
(2012). Loss of serotonin 2A receptors exceeds loss of serotonergic projections
in early Alzheimer’s disease: a combined [11C]DASB and [18F]altanserin-PET
study.Neurobiol. Aging 33, 479–487. doi: 10.1016/j.neurobiolaging.2010.03.023
Martorana, A., and Koch, G. (2014). “Is dopamine involved in Alzheimer’s
disease?”. Front. Aging Neurosci. 6:252. doi: 10.3389/fnagi.2014.
00252
Martorana, A., Mori, F., Esposito, Z., Kusayanagi, H., Monteleone, F., Codecà,
C., et al. (2009). Dopamine modulates cholinergic cortical excitability in
Alzheimer’s disease patients.Neuropsychopharmacology 34, 2323–2328. doi: 10.
1038/npp.2009.60
Masaki, T., Chiba, S., Yasuda, T., Noguchi, H., Kakuma, T., Watanabe, T., et al.
(2004). Involvement of hypothalamic histamine H1 receptor in the regulation
of feeding rhythm and obesity. Diabetes 53, 2250–2260. doi: 10.2337/diabetes.
53.9.2250
Mateo, I., Infante, J., Rodríguez, E., Berciano, J., Combarros, O., and Llorca, J.
(2006). Interaction between dopamine beta-hydroxylase and interleukin genes
increases Alzheimer’s disease risk. J. Neurol. Neurosurg. Psychiatr. 77, 278–279.
doi: 10.1136/jnnp.2005.075358
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., et al.
(2014). Clinical pharmacology of atypical antipsychotics: an update. EXCLI J.
13, 1163–1191.
Mazzucchi, S., Frosini, D., Ripoli, A., Nicoletti, V., Linsalata, G., Bonuccelli,
U., et al. (2015). Serotonergic antidepressant drugs and L-dopa-induced
dyskinesias in Parkinson’s disease. Acta Neurol. Scand. 131, 191–195. doi: 10.
1111/ane.12314
McCann, S. M., Mastronardi, C., de Laurentiis, A., and Rettori, V. (2005). The
nitric oxide theory of aging revisited. Ann. N. Y. Acad. Sci. 1057, 64–84. doi: 10.
1196/annals.1356.064
McCreary, A. C., Varney, M. A., and Newman-Tancredi, A. (2016). The
novel 5-HT1A receptor agonist, NLX-112 reduces L-DOPA-induced abnormal
involuntary movements in rat: a chronic administration study with
microdialysis measurements. Neuropharmacology 105, 651–660. doi: 10.1016/
j.neuropharm.2016.01.013
McDonald, W. M., Richard, I. H., and DeLong, M. R. (2003). Prevalence, etiology,
and treatment of depression in Parkinson’s disease. Biol. Psychiatry 54, 363–375.
doi: 10.1016/S0006-3223(03)00530-4
Melamed, E., Zoldan, J., Friedberg, G., Ziv, I., and Weizmann, A. (1996).
Involvement of serotonin in clinical features of Parkinson’s disease and
complications of L-DOPA therapy. Adv. Neurol. 69, 545–550.
Meltzer, C. C., Smith, G., DeKosky, S. T., Pollock, B. G., Mathis, C. A., Moore,
R. Y., et al. (1998). Serotonin in aging, late-life depression, and Alzheimer’s
disease: the emerging role of functional imaging.Neuropsychopharmacology 18,
407–430. doi: 10.1016/S0893-133X(97)00194-2
Meltzer, H. Y. (1993). New drugs for the treatment of schizophrenia. Psychiatr.
Clin. North Am. 16, 365–385.
Meltzer, H. Y. (1999). Treatment of schizophrenia and spectrum disorders:
pharmacotherapy, psychosocial treatments, and neurotransmitter interactions.
Biol. Psychiatry 46, 1321–1327. doi: 10.1016/S0006-3223(99)00255-3
Meltzer, H. Y., and Huang, M. (2008). In vivo actions of atypical antipsychotic
drug on serotonergic and dopaminergic systems. Prog. Brain Res. 172, 177–197.
doi: 10.1016/S0079-6123(08)00909-6
Meltzer, H. Y., and Massey, B. W. (2011). The role of serotonin receptors in
the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59–67.
doi: 10.1016/j.coph.2011.02.007
Meltzer, H. Y., Matsubara, S., and Lee, J. C. (1989a). Classification of typical and
atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2
pKi values. J. Pharmacol. Exp. Ther. 251, 238–246.
Meltzer, H. Y., Matsubara, S., and Lee, J. C. (1989b). The ratios of serotonin2
and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
Psychopharmacol. Bull. 25, 390–392.
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., et al. (2010).
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of
parkinson’s disease psychosis. Neuropsychopharmacology 35, 881–892. doi: 10.
1038/npp.2009.176
Meltzer, H. Y., and Roth, B. L. (2013). Lorcaserin and pimavanserin: emerging
selectivity of serotonin receptor subtype-targeted drugs. J. Clin. Invest. 123,
4986–4991. doi: 10.1172/JCI70678
Mendez-David, I., David, D. J., Darcet, F., Wu, M. V., Kerdine-Romer,
S., Gardier, A. M., et al. (2014). Rapid anxiolytic effects of a 5-HT(4)
receptor agonist are mediated by a neurogenesis-independent mechanism.
Neuropsychopharmacology 39, 1366–1378. doi: 10.1038/npp.2013.332
Meneses, A. (2013). 5-HT systems: emergent targets for memory formation and
memory alterations. Rev. Neurosci. 24, 629–664. doi: 10.1515/revneuro-2013-
0026
Miguelez, C., Navailles, S., De Deurwaerdere, P., and Ugedo, L. (2016a). The acute
and long-term L-DOPA effects are independent from changes in the activity of
dorsal raphe serotonergic neurons in 6-OHDA lesioned rats. Br. J. Pharmacol.
173, 2135–2146. doi: 10.1111/bph.13447
Frontiers in Neuroscience | www.frontiersin.org 24 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Miguelez, C., Navailles, S., Delaville, C., Marquis, L., Lagière, M., Benazzouz, A.,
et al. (2016b). L-DOPA elicits non-vesicular releases of serotonin and dopamine
in hemiparkinsonian rats in vivo. Eur. Neuropsychopharmacol. 26, 1297–1309.
doi: 10.1016/j.euroneuro.2016.05.004
Millan, M. J. (2005). Serotonin 5-HT2C receptors as a target for the treatment of
depressive and anxious states: focus on novel therapeutic strategies. Therapie
60, 441–460. doi: 10.2515/therapie:2005065
Millan, M. J. (2006). Multi-target strategies for the improved treatment of
depressive states: Conceptual foundations and neuronal substrates, drug
discovery and therapeutic application. Pharmacol. Ther. 110, 135–370. doi: 10.
1016/j.pharmthera.2005.11.006
Millan, M. J. (2010). From the cell to the clinic: a comparative review of the partial
D(2)/D(3)receptor agonist and alpha2-adrenoceptor antagonist, piribedil, in
the treatment of Parkinson’s disease. Pharmacol. Ther. 128, 229–273. doi: 10.
1016/j.pharmthera.2010.06.002
Millan,M. J., Brocco,M., Gobert, A., andDekeyne, A. (2005). Anxiolytic properties
of agomelatine, an antidepressant with melatoninergic and serotonergic
properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 177,
448–458. doi: 10.1007/s00213-004-1962-z
Millan, M. J., Fone, K., Steckler, T., and Horan, W. P. (2014). Negative
symptoms of schizophrenia: clinical characteristics, pathophysiological
substrates, experimental models and prospects for improved treatment. Eur.
Neuropsychopharmacol. 24, 645–692. doi: 10.1016/j.euroneuro.2014.03.008
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., and Ögren, S. O. (2015a).
60 years of advances in neuropsychopharmacology for improving brain health,
renewed hope for progress. Eur. Neuropsychopharmacol. 25, 591–598. doi: 10.
1016/j.euroneuro.2015.01.015
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., and Ove Ögren, S. (2015b).
Learning from the past and looking to the future: emerging perspectives for
improving the treatment of psychiatric disorders. Eur. Neuropsychopharmacol.
25, 599–656. doi: 10.1016/j.euroneuro.2015.01.016
Millan, M. J., Marin, P., Kamal, M., Jockers, R., Chanrion, B., Labasque, M., et al.
(2010). The melatonergic agonist and clinically active antidepressant,
agomelatine, is a neutral antagonist at 5-HT2C receptors. Int. J.
Neuropsychopharmacol. 14, 768–783. doi: 10.1017/S1461145710001045
Morisset, S., Rouleau, A., Ligneau, X., Gbahou, F., Tardivel-Lacombe, J., Stark,
H., et al. (2000). High constitutive activity of native H3 receptors regulates
histamine neurons in brain. Nature 408, 860–864. doi: 10.1038/35048583
Muck-Seler, D., Presecki, P., Mimica, N., Mustapic, M., Pivac, N., Babic, A., et al.
(2009). Platelet serotonin concentration andmonoamine oxidase type B activity
in female patients in early, middle and late phase of Alzheimer’s disease. Prog.
Neuropsychopharmacol. Biol. Psychiatry 33, 1226–1231. doi: 10.1016/j.pnpbp.
2009.07.004
Murphy, D. L., Sims, K. B., Karoum, F., Garrick, N. A., de la Chapelle, A., Sankila, E.
M., et al. (1991). Plasma amine oxidase activities in Norrie disease patients with
an X-chromosomal deletion affecting monoamine oxidase. J. Neural Transm.
Gen. Sect. 83, 1–12. doi: 10.1007/BF01244447
Mustapic, M., Presecki, P., Pivac, N., Mimica, N., Hof, P. R., Simic, G., et al. (2013).
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity
in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 44, 94–99.
doi: 10.1016/j.pnpbp.2013.02.002
Myöhänen, T. T., Schendzielorz, N., and Männistö, P. T. (2010). Distribution
of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in
wild-type and soluble COMT deficient mice. J. Neurochem. 113, 1632–1643.
doi: 10.1111/j.1471-4159.2010.06723.x
Nakazato, T., and Akiyama, A. (1989). Effect of exogenous L-dopa on behavior in
the rat: an in vivo voltammetric study. Brain Res. 490, 332–338. doi: 10.1016/
0006-8993(89)90250-3
Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdère, P. (2010). Serotonergic
neurons mediate ectopic release of dopamine induced by L-DOPA in a rat
model of Parkinson’s disease. Neurobiol. Dis. 38, 136–143. doi: 10.1016/j.nbd.
2010.01.012
Navailles, S., Bioulac, B., Gross, C., and De Deurwaerdère, P. (2011a).
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-
induced dopamine release in a region-dependent manner in a rat model
of Parkinson’s disease. Neurobiol. Dis. 41, 585–590. doi: 10.1016/j.nbd.2010.
11.007
Navailles, S., Carta, M., Guthrie, M., and De Deurwaerdère, P. (2011b). L-DOPA
and serotonergic neurons: functional implication and therapeutic perspectives
in Parkinson’s disease.Cent. Nerv. Syst. Agents Med. Chem. 11, 305–320. doi: 10.
2174/1871524911106040305
Navailles, S., and De Deurwaerdere, P. (2012a). Contribution of serotonergic
transmission to the motor and cognitive effects of high-frequency stimulation
of the subthalamic nucleus or levodopa in Parkinson’s disease.Mol. Neurobiol.
45, 173–185. doi: 10.1007/s12035-011-8230-0
Navailles, S., and De Deurwaerdère, P. (2012b). Imbalanced dopaminergic
transmission mediated by serotonergic neurons in L-DOPA-induced
dyskinesia. Parkinsons. Dis. 2012, 323686. doi: 10.1155/2012/323686
Navailles, S., Di Giovanni, G., and De Deurwaerdère, P. (2015). The 5-HT4 agonist
prucalopride stimulates L-DOPA-induced dopamine release in restricted brain
regions of the hemiparkinsonian rat in vivo. CNS Neurosci. Ther. 21, 745–747.
doi: 10.1111/cns.12436
Navailles, S., Milan, L., Khalki, H., Di Giovanni, G., Lagière, M., and De
Deurwaerdère, P. (2014). Noradrenergic terminals regulate L-DOPA-derived
dopamine extracellular levels in a region-dependent manner in Parkinsonian
rats. CNS Neurosci. Ther. 20, 671–678. doi: 10.1111/cns.12275
Olanow, C. W., Stern, M. B., and Sethi, K. (2009). The scientific and clinical
basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl 4),
S1–S136. doi: 10.1212/wnl.0b013e3181a1d44c
Owen, M. J., Sawa, A., and Mortensen, P. B. (2016). Schizophrenia. Lancet 388,
86–97. doi: 10.1016/S0140-6736(15)01121-6
Page, M. E., Detke, M. J., Dalvi, A., Kirby, L. G., and Lucki, I. (1999). Serotonergic
mediation of the effects of fluoxetine, but not desipramine, in the rat
forced swimming test. Psychopharmacology (Berl). 147, 162–167. doi: 10.1007/
s002130051156
Palmieri, V., Arnett, D. K., Roman, M. J., Liu, J. E., Bella, J. N., Oberman, A., et al.
(2002). Appetite suppressants and valvular heart disease in a population-based
sample: the HyperGEN study. Am. J. Med. 112, 710–715. doi: 10.1016/S0002-
9343(02)01123-3
Panula, P., Chazot, P. L., Cowart,M., Gutzmer, R., Leurs, R., Liu,W. L., et al. (2015).
International union of basic and clinical pharmacology. XCVIII. Histamine
Receptors. Pharmacol Rev 67, 601–655. doi: 10.1124/pr.114.010249
Parsons, C. G., Danysz, W., Dekundy, A., and Pulte, I. (2013). Memantine and
cholinesterase inhibitors: complementary mechanisms in the treatment of
Alzheimer’s disease.Neurotox. Res. 24, 358–369. doi: 10.1007/s12640-013-9398-
z
Pascual, J., Grijalba, B., García-Sevilla, J. A., Zarranz, J. J., and Pazos, A.
(1992). Loss of high-affinity alpha 2-adrenoceptors in Alzheimer’s disease: an
autoradiographic study in frontal cortex and hippocampus. Neurosci. Lett. 142,
36–40. doi: 10.1016/0304-3940(92)90614-D
Payton, S., Cahill, C.M., Randall, J. D., Gullans, S. R., and Rogers, J. T. (2003). Drug
discovery targeted to the Alzheimer’s APP mRNA 5’-untranslated region: the
action of paroxetine and dimercaptopropanol. J. Mol. Neurosci. 20, 267–275.
doi: 10.1385/JMN:20:3:267
Perez-Caballero, L., Torres-Sanchez, S., Bravo, L., Mico, J. A., and Berrocoso, E.
(2014). Fluoxetine: a case history of its discovery and preclinical development.
Expert Opin. Drug Discov. 9, 567–578. doi: 10.1517/17460441.2014.907790
Perez-Lloret, S., and Rascol, O. (2016). Piribedil for the treatment of motor and
non-motor symptoms of Parkinson disease. CNS Drugs. 30, 703–717. doi: 10.
1007/s40263-016-0360-5
Peskind, E. R., Tsuang, D. W., Bonner, L. T., Pascualy, M., Riekse, R. G.,
Snowden, M. B., et al. (2005). Propranolol for disruptive behaviors in nursing
home residents with probable or possible Alzheimer disease: a placebo-
controlled study. Alzheimer Dis. Assoc. Disord. 19, 23–28. doi: 10.1097/01.wad.
0000155067.16313.5e
Piñeyro, G., and Blier, P. (1999). Autoregulation of serotonin neurons: role in
antidepressant drug action. Pharmacol. Rev. 51, 533–591.
Porras, G., De Deurwaerdere, P., Li, Q., Marti, M., Morgenstern, R., Sohr, R., et al.
(2014). L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the
striatum. Sci. Rep. 4:3730. doi: 10.1038/srep03730
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Weizman, R., and Weizman,
A. (2013). Reducing antipsychotic-induced weight gain in schizophrenia: a
double-blind placebo-controlled study of reboxetine-betahistine combination.
Psychopharmacology (Berl). 226, 615–622. doi: 10.1007/s00213-012-2935-2
Frontiers in Neuroscience | www.frontiersin.org 25 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Preda, S., Govoni, S., Lanni, C., Racchi, M., Mura, E., Grilli, M., et al. (2008). Acute
beta-amyloid administration disrupts the cholinergic control of dopamine
release in the nucleus accumbens. Neuropsychopharmacology 33, 1062–1070.
doi: 10.1038/sj.npp.1301485
Provensi, G., Blandina, P., and Passani, M. B. (2016). The histaminergic
system as a target for the prevention of obesity and metabolic syndrome.
Neuropharmacology 106, 3–12. doi: 10.1016/j.neuropharm.2015.07.002
Provensi, G., Coccurello, R., Umehara, H., Munari, L., Giacovazzo, G., Galeotti, N.,
et al. (2014). Satiety factor oleoylethanolamide recruits the brain histaminergic
system to inhibit food intake. Proc. Natl. Acad. Sci. U.S.A. 111, 11527–11532.
doi: 10.1073/pnas.1322016111
Racagni, G., Riva, M. A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., et al.
(2011). Mode of action of agomelatine: synergy between melatonergic and 5-
HT2C receptors.World J. Biol. Psychiatry 12, 574–587. doi: 10.3109/15622975.
2011.595823
Ramirez, M. J., Lai, M. K., Tordera, R. M., and Francis, P. T. (2014). Serotonergic
therapies for cognitive symptoms in Alzheimer’s disease: rationale and current
status. Drugs 74, 729–736. doi: 10.1007/s40265-014-0217-5
Ramsay, R. R. (2013). Inhibitor design for monoamine oxidases. Curr. Pharm. Des.
19, 2529–2539. doi: 10.2174/1381612811319140004
Rantamaki, T., and Yalcin, I. (2016). Antidepressant drug action–
From rapid changes on network function to network rewiring. Prog.
Neuropsychopharmacol. Biol. Psychiatry 64, 285–292. doi: 10.1016/j.pnpbp.
2015.06.001
Rascol, O., Fitzer-Attas, C. J., Hauser, R., Jankovic, J., Lang, A., Langston, J. W.,
et al. (2011). A double-blind, delayed-start trial of rasagiline in Parkinson’s
disease (the ADAGIO study): prespecified and post-hoc analyses of the need
for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Lancet Neurol. 10, 415–423. doi: 10.1016/S1474-4422(11)70073-4
Ratliff, J. C., Barber, J. A., Palmese, L. B., Reutenauer, E. L., and Tek, C. (2010).
Association of prescription H1 antihistamine use with obesity: results from the
National Health and Nutrition Examination Survey.Obesity (Silver. Spring). 18,
2398–2400. doi: 10.1038/oby.2010.176
Reifler, B. V., Teri, L., Raskind, M., Veith, R., Barnes, R., White, E., et al. (1989).
Double-blind trial of imipramine in Alzheimer’s disease patients with and
without depression. Am. J. Psychiatry 146, 45–49. doi: 10.1176/ajp.146.1.45
Remington, G., Foussias, G., Fervaha, G., Agid, O., Takeuchi, H., Lee, J., et al.
(2016). Treating negative symptoms in schizophrenia: an update. Curr Treat
Options Psychiatry 3, 133–150. doi: 10.1007/s40501-016-0075-8
Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parnes, H., Eglen, R. M.,
et al. (1995). 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human
brain tissue: distribution, pharmacology and effects of neurodegenerative
diseases. Br. J. Pharmacol. 114, 993–998. doi: 10.1111/j.1476-5381.1995.
tb13303.x
Rezvani, A. H., Kholdebarin, E., Brucato, F. H., Callahan, P. M., Lowe, D.
A., and Levin, E. D. (2009). Effect of R3487/MEM3454, a novel nicotinic
alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in
rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 269–275. doi: 10.1016/j.
pnpbp.2008.11.018
Richtand, N. M., Welge, J. A., Logue, A. D., Keck, P. E. Jr., Strakowski, S. M., and
McNamara, R. K. (2008). Role of serotonin and dopamine receptor binding
in antipsychotic efficacy. Prog. Brain Res. 172, 155–175. doi: 10.1016/S0079-
6123(08)00908-4
Riederer, P., and Laux, G. (2011). MAO-inhibitors in Parkinson’s disease. Exp.
Neurobiol. 20, 1–17. doi: 10.5607/en.2011.20.1.1
Ries, V., Selzer, R., Eichhorn, T., Oertel, W. H., and Eggert, K. (2010). Replacing
a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa
in the treatment of Parkinson’s disease: a randomized, multicenter, open-label,
parallel-group study. Clin. Neuropharmacol. 33, 142–150. doi: 10.1097/WNF.
0b013e3181d99d6f
Rommelfanger, K. S., andWeinshenker, D. (2007). Norepinephrine: the redheaded
stepchild of Parkinson’s disease. Biochem. Pharmacol. 74, 177–190. doi: 10.
1016/j.bcp.2007.01.036
Rosenzweig-Lipson, S., Comery, T. A., Marquis, K. L., Gross, J., and
Dunlop, J. (2012). 5-HT2C agonists as therapeutics for the treatment of
schizophrenia. Handb. Exp. Pharmacol. 213, 147–165. doi: 10.1007/978-3-642-
25758-2_6
Roth, B. L., and Driscol, J. (2016). Psychoactive Drug Screening Program Ki
Database. Chapel Hill, NC: University of North Carolina at Chapel Hill and
the United States National Institute of Mental Health.
Sachdev, M., Miller, W. C., Ryan, T., and Jollis, J. G. (2002). Effect of fenfluramine-
derivative diet pills on cardiac valves: a meta-analysis of observational studies.
Am. Heart J. 144, 1065–1073. doi: 10.1067/mhj.2002.126733
Sagud, M., Nikolac Perkovic, M., Vuksan-Cusa, B., Maravic, A., Svob Strac, D.,
Mihaljevic Peles, A., et al. (2016). A prospective, longitudinal study of platelet
serotonin and plasma brain-derived neurotrophic factor concentrations in
major depression: effects of vortioxetine treatment. Psychopharmacology (Berl).
233, 3259–3267. doi: 10.1007/s00213-016-4364-0
San, L., and Arranz, B. (2008). Agomelatine: a novel mechanism of antidepressant
action involving the melatonergic and the serotonergic system. Eur. Psychiatry
23, 396–402. doi: 10.1016/j.eurpsy.2008.04.002
Sanchez, C., Asin, K. E., and Artigas, F. (2015). Vortioxetine, a novel antidepressant
with multimodal activity: review of preclinical and clinical data. Pharmacol.
Ther. 145, 43–57. doi: 10.1016/j.pharmthera.2014.07.001
Sanz, E., Quintana, A., Battaglia, V., Toninello, A., Hidalgo, J., Ambrosio, S., et al.
(2008). Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-
2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition
in MPP+-treated SH-SY5Y human dopaminergic cells. J. Neurochem. 105,
2404–2417. doi: 10.1111/j.1471-4159.2008.05326.x
Sanz, E., Romera, M., Bellik, L., Marco, J. I., and Unzeta, M. (2004).
Indolalkylamines derivatives as antioxidant and neuroprotective agents
in an experimental model of Parkinson’s disease. Med. Sci. Monit. 10,
BR477–BR484.
Saura, J., Bleuel, Z., Ulrich, J., Mendelowitsch, A., Chen, K., Shih, J. C., et al.
(1996). Molecular neuroanatomy of human monoamine oxidases A and B
revealed by quantitative enzyme radioautography and in situ hybridization
histochemistry. Neuroscience 70, 755–774. doi: 10.1016/S0306-4522(96)
83013-2
Saura, J., Kettler, R., Da Prada, M., and Richards, J. G. (1992). Quantitative enzyme
radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization
and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and
human brain. J. Neurosci. 12, 1977–1999.
Scheen, A. J. (2010). Cardiovascular risk-benefit profile of sibutramine. Am. J.
Cardiovasc. Drugs 10, 321–334. doi: 10.2165/11584800-000000000-00000
Schendzielorz, N., Oinas, J. P., Myöhänen, T. T., Reenilä, I., Raasmaja,
A., and Männistö, P. T. (2013). Catechol-O-methyltransferase (COMT)
protein expression and activity after dopaminergic and noradrenergic
lesions of the rat brain. PLoS ONE 8:e61392. doi: 10.1371/journal.pone.
0061392
Schreiber, R., and Newman-Tancredi, A. (2014). Improving cognition in
schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A)
receptor activation. Neurobiol. Learn. Mem. 110, 72–80. doi: 10.1016/j.nlm.
2013.12.015
Seeman, P. (2015). Parkinson’s disease treatment may cause impulse-control
disorder via dopamine D3 receptors. Synapse 69, 183–189. doi: 10.1002/syn.
21805
Seeman, P., Chau-Wong, M., Tedesco, J., andWong, K. (1975). Brain receptors for
antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci.
U.S.A. 72, 4376–4380. doi: 10.1073/pnas.72.11.4376
Seeman, P., Lee, T., Chau-Wong, M., and Wong, K. (1976). Antipsychotic drug
doses and neuroleptic/dopamine receptors. Nature 261, 717–719. doi: 10.1038/
261717a0
Shankle, W. R., Nielson, K. A., and Cotman, C. W. (1995). Low-dose propranolol
reduces aggression and agitation resembling that associated with orbitofrontal
dysfunction in elderly demented patients. Alzheimer Dis. Assoc. Disord. 9,
233–237. doi: 10.1097/00002093-199509040-00010
Shen, J. H., Zhao, Y., Rosenzweig-Lipson, S., Popp, D., Williams, J. B., Giller,
E., et al. (2014). A 6-week randomized, double-blind, placebo-controlled,
comparator referenced trial of vabicaserin in acute schizophrenia. J. Psychiatr.
Res. 53, 14–22. doi: 10.1016/j.jpsychires.2014.02.012
Šimic´, G., Babic´ Leko, M., Wray, S., Harrington, C. R., Delalle, I.,
Jovanov-Miloševic´, N., et al. (2016). Monoaminergic neuropathology
in Alzheimer’s disease. Prog. Neurobiol. doi: 10.1016/j.pneurobio.2016.
04.001. [Epub ahead of print].
Frontiers in Neuroscience | www.frontiersin.org 26 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
Simoni, E., Daniele, S., Bottegoni, G., Pizzirani, D., Trincavelli, M. L., Goldoni,
L., et al. (2012). Combining galantamine and memantine in multitargeted, new
chemical entities potentially useful in Alzheimer’s disease. J. Med. Chem. 55,
9708–9721. doi: 10.1021/jm3009458
Sims, N. R., Bowen, D. M., Smith, C. C., Flack, R. H., Davison, A. N., Snowden, J.
S., et al. (1980). Glucose metabolism and acetylcholine synthesis in relation to
neuronal activity in Alzheimer’s disease. Lancet 1, 333–336. doi: 10.1016/S0140-
6736(80)90884-3
Smith, D. J., Salmi, M., Bono, P., Hellman, J., Leu, T., and Jalkanen, S. (1998).
Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion
molecule. J. Exp. Med. 188, 17–27. doi: 10.1084/jem.188.1.17
Solé, M., Hernandez-Guillamon, M., Boada, M., and Unzeta, M. (2008). p53
phosphorylation is involved in vascular cell death induced by the catalytic
activity of membrane-bound SSAO/VAP-1. Biochim. Biophys. Acta 1783,
1085–1094. doi: 10.1016/j.bbamcr.2008.02.014
Solé, M., Minano-Molina, A. J., and Unzeta, M. (2015). Cross-talk between
Abeta and endothelial SSAO/VAP-1 accelerates vascular damage and Abeta
aggregation related to CAA-AD. Neurobiol. Aging 36, 762–775. doi: 10.1016/
j.neurobiolaging.2014.09.030
Stahl, S. M. (2015). Modes and nodes explain the mechanism of action of
vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances
release of serotonin, norepinephrine, and acetylcholine. CNS Spectr. 20,
455–459. doi: 10.1017/S1092852915000346
Stansley, B. J., and Yamamoto, B. K. (2013). L-dopa-induced dopamine synthesis
and oxidative stress in serotonergic cells. Neuropharmacology 67, 243–251.
doi: 10.1016/j.neuropharm.2012.11.010
Stansley, B. J., and Yamamoto, B. K. (2014). Chronic L-dopa decreases serotonin
neurons in a subregion of the dorsal raphe nucleus. J. Pharmacol. Exp. Ther.
351, 440–447. doi: 10.1124/jpet.114.218966
Storga, D., Vrecko, K., Birkmayer, J. G., and Reibnegger, G. (1996).Monoaminergic
neurotransmitters, their precursors and metabolites in brains of Alzheimer
patients. Neurosci. Lett. 203, 29–32. doi: 10.1016/0304-3940(95)12256-7
Strac, D., Pivac, N., Smolders, I. J., Fogel, W., De Deurwaerdere, P., and Di
Giovanni, G. (2016). Monoaminergic mechanisms in epilepsy may offer
innovative therapeutic opportunity for monoaminergic multi-target drugs.
Front. Neurosci. 10:492. doi: 10.3389/fnins.2016.00492
Sun, P., Esteban, G., Inokuchi, T., Marco-Contelles, J., Weksler, B. B., Romero,
I. A., et al. (2015). Protective effect of the multitarget compound DPH-4
on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose
deprivation conditions: an in vitro experimental model of cerebral ischaemia.
Br. J. Pharmacol. 172, 5390–5402. doi: 10.1111/bph.13328
Svenningsson, P., Rosenblad, C., Af Edholm Arvidsson, K., Wictorin, K.,
Keywood, C., Shankar, B., et al. (2015). Eltoprazine counteracts l-DOPA-
induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138(Pt
4), 963–973. doi: 10.1093/brain/awu409
Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., and Raskind,
M. A. (2006). Compensatory changes in the noradrenergic nervous system in
the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s
disease and dementia with Lewy bodies. J. Neurosci. 26, 467–478. doi: 10.1523/
JNEUROSCI.4265-05.2006
Tammimäki, A., Käenmäki, M., Kambur, O., Kulesskaya, N., Keisala, T., Karvonen,
E., et al. (2010). Effect of S-COMT deficiency on behavior and extracellular
brain dopamine concentrations in mice. Psychopharmacology (Berl). 211,
389–401. doi: 10.1007/s00213-010-1944-2
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., and Matsunaga,
M. (1999). Role of serotonergic neurons in L-DOPA-derived extracellular
dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631–634.
doi: 10.1097/00001756-199902250-00034
Taylor, K. M. (1975). “Brain histamine,” in Biochemistry of Biogenic Amines, eds L.
L. Iversen, S. D. Iversen, and S. H. Snyder (New York, NY: Plenum Press New
Yok and London), 327–380. doi: 10.1007/978-1-4684-3171-1_6
Terry, A. V. Jr., Buccafusco, J. J., and Wilson, C. (2008). Cognitive dysfunction in
neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic
targets. Behav. Brain Res. 195, 30–38. doi: 10.1016/j.bbr.2007.12.006
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B.,
Sanger, T. M., et al. (2007). A randomized, double-blind comparison of
olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-
resistant major depressive disorder. J. Clin. Psychiatry 68, 224–236. doi: 10.
4088/JCP.v68n0207
Thomas, D. R., Nelson, D. R., and Johnson, A. M. (1987). Biochemical
effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine
uptake inhibitor. Psychopharmacology (Berl). 93, 193–200. doi: 10.1007/BF001
79933
Tighilet, B., Trottier, S., Mourre, C., Chotard, C., and Lacour, M. (2002).
Betahistine dihydrochloride interaction with the histaminergic system in the
cat: neurochemical and molecular mechanisms. Eur. J. Pharmacol. 446, 63–73.
doi: 10.1016/S0014-2999(02)01795-8
Tohgi, H., Ueno, M., Abe, T., Takahashi, S., and Nozaki, Y. (1992). Concentrations
of monoamines and their metabolites in the cerebrospinal fluid from patients
with senile dementia of the Alzheimer type and vascular dementia of the
Binswanger type. J. Neural Transm. Park. Dis. Dement. Sect. 4, 69–77. doi: 10.
1007/BF02257623
Tonelli, M., Catto, M., Tasso, B., Novelli, F., Canu, C., Iusco, G., et al. (2015).
Multitarget therapeutic leads for Alzheimer’s disease: quinolizidinyl derivatives
of Bi- and tricyclic systems as dual inhibitors of cholinesterases and beta-
amyloid (Abeta) aggregation. ChemMedChem 10, 1040–1053. doi: 10.1002/
cmdc.201500104
Torres, G. E., Gainetdinov, R. R., and Caron, M. G. (2003). Plasma membrane
monoamine transporters: structure, regulation and function. Nat. Rev.
Neurosci. 4, 13–25. doi: 10.1038/nrn1008
Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., et al.
(2013). Ascending monoaminergic systems alterations in Alzheimer’s disease.
Translating basic science into clinical care. Neurosci. Biobehav. Rev. 37,
1363–1379. doi: 10.1016/j.neubiorev.2013.05.008
Tronci, E., Fidalgo, C., Stancampiano, R., and Carta, M. (2015). Effect of
selective and non-selective serotonin receptor activation on l-DOPA-induced
therapeutic efficacy and dyskinesia in parkinsonian rats. Behav. Brain Res. 292,
300–304. doi: 10.1016/j.bbr.2015.06.034
Udenfriend, S., Weissbach, H., and Bogdanski, D. F. (1957). Effect of
iproniazid on serotonin metabolism in vivo. J. Pharmacol. Exp. Ther. 120,
255–260.
Versijpt, J., Van Laere, K. J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P.,
et al. (2003). Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s
disease-related findings. Neurobiol. Aging 24, 553–561. doi: 10.1016/S0197-
4580(02)00137-9
Vickers, S. P., Dourish, C. T., and Kennett, G. A. (2001). Evidence that hypophagia
induced by d-fenfluramine and d-norfenfluramine in the rat is mediated
by 5-HT2C receptors. Neuropharmacology 41, 200–209. doi: 10.1016/S0028-
3908(01)00063-6
Visanji, N. P., Fox, S. H., Johnston, T., Reyes, G., Millan, M. J., and Brotchie, J.
M. (2009). Dopamine D3 receptor stimulation underlies the development of L-
DOPA-induced dyskinesia in animal models of Parkinson’s disease. Neurobiol.
Dis. 35, 184–192. doi: 10.1016/j.nbd.2008.11.010
Vivero, L. E., Anderson, P. O., and Clark, R. F. (1998). A close look at
fenfluramine and dexfenfluramine. J. Emerg. Med. 16, 197–205. doi: 10.1016/
S0736-4679(97)00289-8
Voigt, J. P., and Fink, H. (2015). Serotonin controlling feeding and satiety. Behav.
Brain Res. 277, 14–31. doi: 10.1016/j.bbr.2014.08.065
Werner, F. M., and Covenas, R. (2016). Serotonergic drugs: agonists/antagonists
at specific serotonergic subreceptors for the treatment of cognitive, depressant
and psychotic symptoms in Alzheimer’s disease. Curr. Pharm. Des. 22,
2064–2071. doi: 10.2174/1381612822666160127113524
Wimalasena, K. (2011). Vesicular monoamine transporters: structure-function,
pharmacology, and medicinal chemistry. Med. Res. Rev. 31, 483–519. doi: 10.
1002/med.20187
Wong, D. T., Bymaster, F. P., Horng, J. S., and Molloy, B. B. (1975). A new
selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-
trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. J. Pharmacol. Exp.
Ther. 193, 804–811.
Yan, W., Zhao, C., Sun, L., and Tang, B. (2016). Association between
polymorphism of COMT gene (Val158Met) with Alzheimer’s disease: an
updated analysis. J. Neurol. Sci. 361, 250–255. doi: 10.1016/j.jns.2016.
01.014
Youdim,M. B., Edmondson, D., and Tipton, K. F. (2006). The therapeutic potential
of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7, 295–309. doi: 10.1038/
nrn1883
Yu, P. H., andDeng, Y. L. (1998). Endogenous formaldehyde as a potential factor of
vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine
Frontiers in Neuroscience | www.frontiersin.org 27 November 2016 | Volume 10 | Article 541
Di Giovanni et al. Monoaminergic Targets and Neuropsychiatry
oxidase-mediated methylamine turnover. Atherosclerosis 140, 357–363. doi: 10.
1016/S0021-9150(98)00142-7
Zeller, E. A., and Barsky, J. (1952). In vivo inhibition of liver and brain monoamine
oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med. 81,
459–461. doi: 10.3181/00379727-81-19910
Zlokovic, B. V. (2008). New therapeutic targets in the neurovascular pathway
in Alzheimer’s disease. Neurotherapeutics 5, 409–414. doi: 10.1016/j.nurt.2008.
05.011
Zohar, J., Stahl, S., Moller, H. J., Blier, P., Kupfer, D., Yamawaki, S.,
et al. (2015). A review of the current nomenclature for psychotropic
agents and an introduction to the neuroscience-based nomenclature. Eur.
Neuropsychopharmacol. 25, 2318–2325. doi: 10.1016/j.euroneuro.2015.08.019
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Di Giovanni, Svob Strac, Sole, Unzeta, Tipton, Mück-Šeler, Bolea,
Della Corte, Nikolac Perkovic, Pivac, Smolders, Stasiak, Fogel and De Deurwaerdère.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 28 November 2016 | Volume 10 | Article 541
